<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VYTORIN- ezetimibe and simvastatinÂ tabletÂ </strong><br>Rebel Distributors Corp<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use VYTORIN safely and effectively. See full prescribing information for VYTORIN.<br><br>VYTORIN (ezetimibe/simvastatin) Tablets<br>Initial U.S. Approval: 2004</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Dosage and Administration </p>
<p class="Highlighta">Â Â Â Â Â Chinese Patients Taking Lipid-Modifying Doses (â‰¥1Â g/day Niacin) of<br>Â Â Â Â Â Niacin-Containing Products (<a href="#i4i_section_id_27de2ec7-d73c-43fe-bc53-a5bb9d4c1ab2">2.6</a>) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 03/2010 </p>
<p class="Highlighta">Â Â Â Â Â Coadministration with Other Drugs (<a href="#i4i_section_id_b26a6a53-5c8d-4643-860c-d873eb4c4c2d">2.7</a>) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 03/2010 </p>
<p class="Highlighta">Warnings and Precautions </p>
<p class="Highlighta">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> (<a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">5.1</a>) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 03/2010 </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">VYTORIN<span class="Sup">Â®</span>, which contains a <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> absorption inhibitor and an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet to: </p>
<ul>
<li>reduce elevated total-C, LDL-C, ApoÂ B, TG, and non-HDL-C, and to increase HDL-C in patients with primary (heterozygous familial and non-familial) <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> or mixed <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>. (<a href="#i4i_section_id_738c4622-f1ff-4be7-a1cc-a87f7d56db88">1.1</a>)</li>
<li>reduce elevated total-C and LDL-C in patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">homozygous familial hypercholesterolemia</span> (HoFH), as an adjunct to other lipid-lowering treatments. (<a href="#i4i_section_id_d93f0bc7-9f0e-4251-8f80-02ff64611b84">1.2</a>)</li>
</ul>
<p class="Highlighta">Limitations of Use (<a href="#i4i_section_id_3c755fc3-72c7-4d88-88fa-8e57428a75c2">1.3</a>) </p>
<ul><li>No incremental benefit of VYTORIN on cardiovascular morbidity and mortality over and above that demonstrated for simvastatin has been established. VYTORIN has not been studied in Fredrickson Type I, III, IV, and V <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemias</span>.</li></ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Dosage range is 10/10Â mg/day through 10/80Â mg/day. (<a href="#i4i_section_id_669e9576-0e9b-4008-a57d-00d76f7c6852">2.1</a>)</li>
<li>Recommended usual starting dose is 10/20Â mg/day. <a href="#i4i_section_id_669e9576-0e9b-4008-a57d-00d76f7c6852">(2.1)</a>
</li>
<li>Dosing of VYTORIN should occur either â‰¥2Â hours before or â‰¥4Â hours after administration of a bile acid sequestrant. (<a href="#i4i_section_id_b26a6a53-5c8d-4643-860c-d873eb4c4c2d">2.7</a>, <a href="#i4i_section_id_da6c7251-4498-439b-aa1e-1c443a7e1c14">7.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Tablets (ezetimibeÂ mg/simvastatinÂ mg): 10/10, 10/20, 10/40, 10/80 (<a href="#i4i_dosage_form_strength_id_f4f0ec14-31e9-42f7-ac03-a4d671ad6c75">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this medication (<a href="#i4i_contraindications_id_9e30296b-de48-4816-9c39-6a8ec2edca07">4</a>, <a href="#i4i_section_id_144b0df7-7c0e-4544-9b72-eade599d6274">6.2</a>)</li>
<li>Active liver disease or unexplained persistent elevations of hepatic transaminase levels (<a href="#i4i_contraindications_id_9e30296b-de48-4816-9c39-6a8ec2edca07">4</a>, <a href="#i4i_section_id_8ed6c1e8-7476-4ac3-8f7d-bfa4f3fc1ca0">5.2</a>)</li>
<li>Women who are pregnant or may become pregnant (<a href="#i4i_contraindications_id_9e30296b-de48-4816-9c39-6a8ec2edca07">4</a>, <a href="#i4i_pregnancy_id_1d00559e-220c-4a6e-bf52-2ccf7690635f">8.1</a>)</li>
<li>Nursing mothers (<a href="#i4i_contraindications_id_9e30296b-de48-4816-9c39-6a8ec2edca07">4</a>, <a href="#i4i_nursing_mothers_id_a37c37f4-681b-4fa4-a794-fd895cf1f36e">8.3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Patients should be advised to report promptly any symptoms of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>. VYTORIN should be discontinued immediately if <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is diagnosed or suspected. (<a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">5.1</a>)</li>
<li>Skeletal muscle effects (e.g., <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>): Risks increase with higher doses and concomitant use of certain CYP3A4 inhibitors, gemfibrozil, cyclosporine, danazol, amiodarone, verapamil, and diltiazem. Predisposing factors include advanced age (â‰¥65), uncontrolled <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (<a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">5.1</a>, <a href="#i4i_geriatric_use_id_a62fff98-a7ad-4f1e-8b82-4b3cc3b71988">8.5</a>, <a href="#i4i_section_id_181c96b0-b591-4845-95e9-0478f4d55f3a">8.6</a>)</li>
<li>Liver enzyme abnormalities and monitoring: Persistent elevations in hepatic transaminase can occur. Monitor liver enzymes before and during treatment. Patients titrated to the 10/80-mg dose should receive additional liver function tests. (<a href="#i4i_section_id_8ed6c1e8-7476-4ac3-8f7d-bfa4f3fc1ca0">5.2</a>)</li>
<li>VYTORIN is not recommended in patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#i4i_section_id_01b37490-d8c9-4725-b1be-157b86f9d57f">5.3</a>, <a href="#i4i_pharmacokinetics_id_54aca0d2-b6db-489e-9580-e37ab482aec5">12.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><ul><li>Common (incidence â‰¥2% and greater than placebo) adverse reactions in clinical trials: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, increased ALT, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. (<a href="#i4i_section_id_f9bd7b74-9faf-41ee-9c69-df371172df46">6.1</a>)<p class="Highlighta"><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Merck/Schering-Plough Pharmaceuticals at 1-866-637-2501 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</li></ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<a name="id_00bb65e2-c021-46c4-9f3a-3a4f1bd81da1"></a><table>
<caption><span>Drug Interactions Associated with Increased Risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> (<a href="#i4i_section_id_b26a6a53-5c8d-4643-860c-d873eb4c4c2d">2.7</a>, <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">5.1</a>, <a href="#i4i_section_id_a38e88d3-256e-407c-ac33-448a99fc7a64">7.1</a>, <a href="#i4i_section_id_b395b70f-0d19-4d5c-8d61-55033f3eeb9d">7.2</a>, <a href="#i4i_section_id_a0181393-2d82-4d35-bdb7-b15176640029">7.3</a>, <a href="#i4i_section_id_0f2702c7-2df5-4904-a0b4-43eec959f819">7.6</a>, <a href="#i4i_section_id_d14fc525-3963-4234-a3e6-a76b1b33cfd0">7.8</a>)</span></caption>
<col width="50.4%">
<col width="49.6%">
<thead><tr class="First Last">
<td class="Botrule" align="center" valign="top"><span class="Bold">Interacting Agents</span></td>
<td class="Botrule" align="left" valign="top"><span class="Bold">Prescribing Recommendations</span></td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">Itraconazole,<br>ketoconazole,<br>erythromycin,<br>clarithromycin,<br>telithromycin, HIV protease inhibitors, <br>nefazodone,<br>fibrates</td>
<td class="Botrule" align="left" valign="top">Avoid VYTORIN</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Cyclosporine, danazol</td>
<td class="Botrule" align="left" valign="top">Do not exceed 10/10Â mg VYTORIN daily</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Amiodarone, verapamil</td>
<td class="Botrule" align="left" valign="top">Do not exceed 10/20Â mg VYTORIN daily</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Diltiazem</td>
<td class="Botrule" align="left" valign="top">Do not exceed 10/40Â mg VYTORIN daily</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Grapefruit juice</td>
<td class="Botrule" align="left" valign="top">Avoid large quantities of grapefruit juice (&gt;1Â quart daily)</td>
</tr>
</tbody>
</table>
<ul>
<li>Cyclosporine: Combination increases exposure of ezetimibe and cyclosporine. Cyclosporine concentrations should be monitored. (<a href="#i4i_section_id_0f2702c7-2df5-4904-a0b4-43eec959f819">7.6</a>, <a href="#i4i_pharmacokinetics_id_54aca0d2-b6db-489e-9580-e37ab482aec5">12.3</a>)</li>
<li>Coumarin anticoagulants: simvastatin prolongs INR. Achieve stable INR prior to starting VYTORIN. Monitor INR frequently until stable upon initiation or alteration of VYTORIN therapy. (<a href="#i4i_section_id_ad784484-4573-42ce-be7d-7a37ce89b061">7.9</a>)</li>
<li>Cholestyramine: Combination decreases exposure of ezetimibe. (<a href="#i4i_section_id_b26a6a53-5c8d-4643-860c-d873eb4c4c2d">2.7</a>, <a href="#i4i_section_id_da6c7251-4498-439b-aa1e-1c443a7e1c14">7.5</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul><li>Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>: Caution should be exercised and the patient should be closely monitored. (<a href="#i4i_section_id_dbf7935b-8836-43e8-9f19-89ff556d10d9">2.4</a>, <a href="#i4i_section_id_181c96b0-b591-4845-95e9-0478f4d55f3a">8.6</a>)</li></ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 5/2010</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span> (HoFH)</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Limitations of Use</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dosing</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Geriatric Patients</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Chinese Patients Taking Lipid-Modifying Doses (â‰¥1 g/day Niacin) of Niacin-Containing Products</a></h2>
<h2><a href="#section-2.7" class="toc">2.7 Coadministration with Other Drugs</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Liver Enzymes</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 CYP3A4 Interactions</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Lipid-Lowering Drugs That Can Cause <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> When Given Alone</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Amiodarone, Verapamil, or Diltiazem</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Niacin</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Cholestyramine</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Cyclosporine or Danazol</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Digoxin</a></h2>
<h2><a href="#section-7.8" class="toc">7.8 Fibrates</a></h2>
<h2><a href="#section-7.9" class="toc">7.9 Coumarin Anticoagulants</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span> (HoFH)</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle Pain</span></a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Liver Enzymes</a></h2>
<h2><a href="#section-15.3" class="toc">17.3 Pregnancy</a></h2>
<h2><a href="#section-15.4" class="toc">17.4 Breast-feeding</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_f2d84433-5db4-412d-9f9b-cfaafebadce9"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and other nonpharmacologic measures alone has been inadequate.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_738c4622-f1ff-4be7-a1cc-a87f7d56db88"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></h2>
<p class="First">VYTORIN is indicated for the reduction of elevated total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (total-C), low-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (LDL-C), <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> B (ApoÂ B), triglycerides (TG), and non-high-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (non-HDL-C), and to increase high-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (HDL-C) in patients with primary (heterozygous familial and non-familial) <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> or mixed <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d93f0bc7-9f0e-4251-8f80-02ff64611b84"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span> (HoFH)</h2>
<p class="First">VYTORIN is indicated for the reduction of elevated total-C and LDL-C in patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">homozygous familial hypercholesterolemia</span>, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3c755fc3-72c7-4d88-88fa-8e57428a75c2"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Limitations of Use</h2>
<p class="First">No incremental benefit of VYTORIN on cardiovascular morbidity and mortality over and above that demonstrated for simvastatin has been established. VYTORIN has not been studied in Fredrickson type I, III, IV, and V <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemias</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_c681ef41-178a-416e-94f4-62842d3f80f1"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_669e9576-0e9b-4008-a57d-00d76f7c6852"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dosing</h2>
<p class="First">The dosage range is 10/10Â mg/day through 10/80Â mg/day. The recommended usual starting dose is 10/20Â mg/day. VYTORIN should be taken as a single daily dose in the evening, with or without food. Initiation of therapy with 10/10Â mg/day may be considered for patients requiring less aggressive LDL-C reductions. Patients who require a larger reduction in LDL-C (greater than 55%) may be started at 10/40Â mg/day. After initiation or titration of VYTORIN, lipid levels may be analyzed after 2 or more weeks and dosage adjusted, if needed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_11a8d168-2adf-44ee-b595-f88fc2266f2b"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span></h2>
<p class="First">The recommended dosage for patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">homozygous familial hypercholesterolemia</span> is VYTORIN 10/40Â mg/day or 10/80Â mg/day in the evening. VYTORIN should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_112b16d8-2f8f-4e57-9229-fdb648c363e1"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No dosage adjustment is necessary in patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#i4i_section_id_01b37490-d8c9-4725-b1be-157b86f9d57f">Warnings and Precautions (5.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dbf7935b-8836-43e8-9f19-89ff556d10d9"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dosage adjustment is necessary in patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. However, for patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, VYTORIN should not be started unless the patient has already tolerated treatment with simvastatin at a dose of 5Â mg or higher. Caution should be exercised when VYTORIN is administered to these patients, and they should be closely monitored <span class="Italics">[see <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a>; <a href="#i4i_pharmacokinetics_id_54aca0d2-b6db-489e-9580-e37ab482aec5">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_78b7e99d-a6da-46c8-bdd2-f00601eb1508"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Geriatric Patients</h2>
<p class="First">No dosage adjustment is necessary in geriatric patients <span class="Italics">[see <a href="#i4i_pharmacokinetics_id_54aca0d2-b6db-489e-9580-e37ab482aec5">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_27de2ec7-d73c-43fe-bc53-a5bb9d4c1ab2"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Chinese Patients Taking Lipid-Modifying Doses (â‰¥1 g/day Niacin) of Niacin-Containing Products</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Because of an increased risk for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, caution should be used when treating Chinese patients with VYTORIN coadministered with lipid-modifying doses (â‰¥1Â g/day niacin) of niacin-containing products. Because the risk for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is dose-related, Chinese patients should not receive VYTORIN 10/80Â mg coadministered with lipid-modifying doses of niacin-containing products. The cause of the increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is not known. It is also unknown if the risk for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> with coadministration of simvastatin with lipid-modifying doses of niacin-containing products observed in Chinese patients applies to other Asian patients. <span class="Italics">[See <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a>.]</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b26a6a53-5c8d-4643-860c-d873eb4c4c2d"></a><a name="section-2.7"></a><p></p>
<h2>2.7 Coadministration with Other Drugs</h2>
<p class="First"><span class="Italics">[See <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a> and <a href="#i4i_interactions_id_acfc6456-bb28-460c-894d-cb2af80b4e02">Drug Interactions (7)</a>.]</span></p>
<p><span class="Italics"><span class="Bold">Bile Acid Sequestrants</span></span></p>
<p>Dosing of VYTORIN should occur either â‰¥2Â hours before or â‰¥4Â hours after administration of a bile acid sequestrant <span class="Italics">[see <a href="#i4i_section_id_da6c7251-4498-439b-aa1e-1c443a7e1c14">Drug Interactions (7.5)</a>]</span>.</p>
<p><span class="Italics"><span class="Bold">Cyclosporine or Danazol</span></span></p>
<p>Caution should be exercised when initiating VYTORIN in the setting of cyclosporine. In patients taking cyclosporine or danazol, VYTORIN should not be started unless the patient has already tolerated treatment with simvastatin at a dose of 5Â mg or higher. The dose of VYTORIN should not exceed 10/10Â mg/day <span class="Italics">[see <a href="#i4i_section_id_0f2702c7-2df5-4904-a0b4-43eec959f819">Drug Interactions (7.6)</a>]</span>.</p>
<p><span class="Bold"><span class="Italics">Amiodarone or Verapamil</span></span></p>
<p>In patients taking amiodarone or verapamil concomitantly with VYTORIN, the dose should not exceed 10/20Â mg/day <span class="Italics">[see <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a> and <a href="#i4i_section_id_a0181393-2d82-4d35-bdb7-b15176640029">Drug Interactions (7.3)</a>]</span>.</p>
<p><span class="Bold"><span class="Italics">Diltiazem</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">The dose of VYTORIN should not exceed 10/40Â mg/day <span class="Italics">[see <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a>, <a href="#i4i_section_id_a0181393-2d82-4d35-bdb7-b15176640029">Drug Interactions (7.3)</a>, and <a href="#i4i_pharmacokinetics_id_54aca0d2-b6db-489e-9580-e37ab482aec5">Clinical Pharmacology (12.3)</a>]</span>.</span></p>
<p><span class="Italics"><span class="Bold">Other Concomitant Lipid-Lowering Therapy</span></span></p>
<p>The safety and effectiveness of VYTORIN administered with fibrates have not been established. Therefore, the combination of VYTORIN and fibrates should be avoided <span class="Italics">[see <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a> and <a href="#i4i_section_id_b395b70f-0d19-4d5c-8d61-55033f3eeb9d">Drug Interactions (7.2</a> and <a href="#i4i_section_id_d14fc525-3963-4234-a3e6-a76b1b33cfd0">7.8)</a>]</span>.</p>
<p>There is an increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> when simvastatin is used concomitantly with fibrates (especially gemfibrozil). Combination therapy with gemfibrozil should be avoided because of an increase in simvastatin exposure with concomitant use. <span class="Italics">[See <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a> and <a href="#i4i_section_id_b395b70f-0d19-4d5c-8d61-55033f3eeb9d">Drug Interactions (7.2</a> and <a href="#i4i_section_id_d14fc525-3963-4234-a3e6-a76b1b33cfd0">7.8)</a>.]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_f4f0ec14-31e9-42f7-ac03-a4d671ad6c75"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<ul>
<li>VYTORIN<span class="Sup">Â®</span> 10/10, (ezetimibe 10Â mg/simvastatin 10Â mg tablets) are white to off-white capsule-shaped tablets with code â€œ311â€? on one side.</li>
<li>VYTORIN<span class="Sup">Â®</span> 10/20, (ezetimibe 10Â mg/simvastatin 20Â mg tablets) are white to off-white capsule-shaped tablets with code â€œ312â€? on one side.</li>
<li>VYTORIN<span class="Sup">Â®</span> 10/40, (ezetimibe 10Â mg/simvastatin 40Â mg tablets) are white to off-white capsule-shaped tablets with code â€œ313â€? on one side.</li>
<li>VYTORIN<span class="Sup">Â®</span> 10/80, (ezetimibe 10Â mg/simvastatin 80Â mg tablets) are white to off-white capsule-shaped tablets with code â€œ315â€? on one side.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_9e30296b-de48-4816-9c39-6a8ec2edca07"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this medication <span class="Italics">[see <a href="#i4i_section_id_144b0df7-7c0e-4544-9b72-eade599d6274">Adverse Reactions (6.2)</a>]</span>.</p>
<p>Active liver disease or unexplained persistent elevations in hepatic transaminase levels <span class="Italics">[see <a href="#i4i_section_id_8ed6c1e8-7476-4ac3-8f7d-bfa4f3fc1ca0">Warnings and Precautions (5.2)</a>]</span>.</p>
<p>Women who are pregnant or may become pregnant. Serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides increase during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span>, and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> derivatives are essential for fetal development. Because HMG-CoA reductase inhibitors (statins), such as simvastatin, decrease <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis and possibly the synthesis of other biologically active substances derived from <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, VYTORIN may cause fetal harm when administered to a pregnant woman. <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>. There are no adequate and well-controlled studies of VYTORIN use during pregnancy; however, in rare reports congenital anomalies were observed following intrauterine exposure to statins. In rat and rabbit animal reproduction studies, simvastatin revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. <span class="Bold">VYTORIN should be administered to women of childbearing age only when such patients are highly unlikely to conceive.</span> If the patient becomes pregnant while taking this drug, VYTORIN should be discontinued immediately and the patient should be apprised of the potential hazard to the fetus <span class="Italics">[see <a href="#i4i_pregnancy_id_1d00559e-220c-4a6e-bf52-2ccf7690635f">Use in Specific Populations (8.1)</a>]</span>.</p>
<p>Nursing mothers. It is not known whether simvastatin is excreted into human milk; however, a small amount of another drug in this class does pass into breast milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require VYTORIN treatment should not breast-feed their infants <span class="Italics">[see <a href="#i4i_nursing_mothers_id_a37c37f4-681b-4fa4-a794-fd895cf1f36e">Use in Specific Populations (8.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_70b06de5-0742-49c7-ac21-2ff01785ea9a"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span></h2>
<p class="First">In clinical trials, there was no excess of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> or <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> associated with ezetimibe compared with the relevant control arm (placebo or statin alone). However, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> are known adverse reactions to statins and other lipid-lowering drugs. In clinical trials, the incidence of CK &gt;10 X the upper limit of normal (ULN) was 0.2% for VYTORIN, 0.6% for placebo, 0.0% for ezetimibe, and 0.3% for all simvastatin doses.</p>
<p>Simvastatin, like other statins, occasionally causes <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> manifested as <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> with creatine kinase above 10 X ULN. <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> sometimes takes the form of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> with or without <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span>, and rare fatalities have occurred. The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is increased by high levels of statin activity in plasma. Predisposing factors for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> include advanced age (â‰¥65Â years), uncontrolled <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p><span class="Bold">As with other statins, the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> is dose related.</span> In a clinical trial database in which 41,050 patients were treated with simvastatin with 24,747 (approximately 60%) treated for at least 4Â years, the incidence of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> was approximately 0.02%, 0.08% and 0.53% at 20, 40 and 80Â mg/day, respectively. In these trials, patients were carefully monitored and some interacting medicinal products were excluded.</p>
<p>In post-marketing experience with ezetimibe, cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported. Most patients who developed <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> were taking a statin prior to initiating ezetimibe. However, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> has been reported very rarely with ezetimibe monotherapy and very rarely with the addition of ezetimibe to agents known to be associated with increased risk of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, such as fibrates.</p>
<p><span class="Bold">All patients starting therapy with VYTORIN or whose dose of VYTORIN is being increased should be advised of the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and told to report promptly any unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. VYTORIN therapy should be discontinued immediately if <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is diagnosed or suspected.</span> In most cases, muscle symptoms and CK increases resolved when simvastatin treatment was promptly discontinued. Periodic CK determinations may be considered in patients starting therapy with simvastatin or whose dose is being increased, but there is no assurance that such monitoring will prevent <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>. </p>
<p>Many of the patients who have developed <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> on therapy with simvastatin have had complicated medical histories, including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> usually as a consequence of long-standing <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. Such patients taking VYTORIN merit closer monitoring. Therapy with VYTORIN should be temporarily stopped a few days prior to elective major surgery and when any major medical or surgical condition supervenes.</p>
<p><br><span class="Italics">Drug Interactions</span></p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> is increased by high levels of statin activity in plasma. Simvastatin is metabolized by the cytochrome P450 isoform 3A4. Certain drugs that inhibit this metabolic pathway can raise the plasma levels of simvastatin and may increase the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>. These include itraconazole, ketoconazole, and other antifungal azoles, the macrolide antibiotics erythromycin and clarithromycin, and the ketolide antibiotic telithromycin, HIV protease inhibitors, the antidepressant nefazodone, or large quantities of grapefruit juice (&gt;1Â quart daily). The use of VYTORIN concomitantly with these CYP3A4 inhibitors should be avoided. If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with VYTORIN should be suspended during the course of treatment. <span class="Italics">[See <a href="#i4i_interactions_id_acfc6456-bb28-460c-894d-cb2af80b4e02">Drug Interactions (7)</a>.]</span></p>
<p style="border-left:1px solid;"><span class="XmChange">The benefits of the combined use of VYTORIN with the following drugs should be carefully weighed against the potential risks of combinations: gemfibrozil, other lipid-lowering drugs (other fibrates or â‰¥1Â g/day of niacin), cyclosporine, danazol, amiodarone, verapamil, or diltiazem.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Caution should be used when prescribing other fibrates with VYTORIN, as these agents can cause <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> when given alone.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been observed with simvastatin coadministered with lipid-modifying doses (â‰¥1Â g/day niacin) of niacin-containing products. In an ongoing, double-blind, randomized cardiovascular outcomes trial, an independent safety monitoring committee identified that the incidence of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is higher in Chinese compared with non-Chinese patients taking simvastatin 40Â mg or ezetimibe/simvastatin 10/40Â mg coadministered with lipid-modifying doses of a niacin-containing product. Because the risk for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is dose-related, Chinese patients should not receive VYTORIN 10/80Â mg coadministered with lipid-modifying doses of niacin-containing products. It is unknown if the risk for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> with coadministration of simvastatin with lipid-modifying doses of niacin-containing products observed in Chinese patients applies to other Asian patients.</span></p>
<p>Prescribing recommendations for interacting agents are summarized in TableÂ 1 <span class="Italics">[see also <a href="#i4i_section_id_b26a6a53-5c8d-4643-860c-d873eb4c4c2d">Dosage and Administration (2.7)</a>, <a href="#i4i_interactions_id_acfc6456-bb28-460c-894d-cb2af80b4e02">Drug Interactions (7)</a>, and <a href="#i4i_pharmacokinetics_id_54aca0d2-b6db-489e-9580-e37ab482aec5">Clinical Pharmacology (12.3)</a>]</span>.</p>
<a name="id_5f98a814-bbcf-4ff5-848b-be03d982b11f"></a><table width="500.000">
<caption><span>Table 1: Drug Interactions Associated with Increased Risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span></span></caption>
<col width="40.0%">
<col width="60.0%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="top">Interacting Agents</td>
<td class="Botrule" align="left" valign="top">Prescribing Recommendations </td>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Combination therapy with fibrates should be avoided; however, although not recommended, if VYTORIN is used in combination with gemfibrozil, the dose should not exceed 10/10Â mg daily.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">â€ </a></dt>
<dd>The benefits of the use of VYTORIN in patients receiving cyclosporine or danazol should be carefully weighed against the risks of these combinations.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">â€¡</a></dt>
<dd>The combined use of VYTORIN at doses higher than 10/20Â mg daily with amiodarone or verapamil should be avoided unless the clinical benefit is likely to outweigh the increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">Â§</a></dt>
<dd><span class="XmChange">The combined use of VYTORIN at doses higher than 10/40Â mg daily with diltiazem should be avoided unless the clinical benefit is likely to outweigh the increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>.</span></dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">Itraconazole<br>Ketoconazole<br>Erythromycin<br>Clarithromycin<br>Telithromycin<br>HIV protease inhibitors<br>Nefazodone<br>Fibrates<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td class="Botrule" align="left" valign="top">Avoid VYTORIN</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Cyclosporine<a name="footnote-reference-2" href="#footnote-2" class="Sup">â€ </a><br>Danazol<a href="#footnote-2" class="Sup">â€ </a>
</td>
<td class="Botrule" align="left" valign="top">Do not exceed 10/10Â mg VYTORIN daily</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Amiodarone<a name="footnote-reference-3" href="#footnote-3" class="Sup">â€¡</a><br>Verapamil<a href="#footnote-3" class="Sup">â€¡</a>
</td>
<td class="Botrule" align="left" valign="top">Do not exceed 10/20Â mg VYTORIN daily</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="XmChange">Diltiazem<a name="footnote-reference-4" href="#footnote-4" class="Sup">Â§</a></span></td>
<td class="Botrule" align="left" valign="top"><span class="XmChange">Do not exceed 10/40Â mg VYTORIN daily</span></td>
</tr>
<tr class="Last">
<td class="Botrule" align="justify" valign="top">Grapefruit juice</td>
<td class="Botrule" align="justify" valign="top">Avoid large quantities of grapefruit juice (&gt;1Â quart daily)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8ed6c1e8-7476-4ac3-8f7d-bfa4f3fc1ca0"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Liver Enzymes</h2>
<p class="First">In three placebo-controlled, 12-week trials, the incidence of consecutive elevations (â‰¥3 X ULN) in serum transaminases was 1.7% overall for patients treated with VYTORIN and appeared to be dose-related with an incidence of 2.6% for patients treated with VYTORIN 10/80. In controlled long-term (48-week) extensions, which included both newly-treated and previously-treated patients, the incidence of consecutive elevations (â‰¥3 X ULN) in serum transaminases was 1.8% overall and 3.6% for patients treated with VYTORIN 10/80. These elevations in transaminases were generally asymptomatic, not associated with <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, and returned to baseline after discontinuation of therapy or with continued treatment.</p>
<p>It is recommended that liver function tests be performed before the initiation of treatment with VYTORIN, and thereafter when clinically indicated. Patients titrated to the 10/80-mg dose should receive an additional test prior to titration, 3Â months after titration to the 10/80-mg dose, and periodically thereafter (e.g., semiannually) for the first year of treatment. Patients who develop increased transaminase levels should be monitored with a second liver function evaluation to confirm the finding and be followed thereafter with frequent liver function tests until the abnormality(ies) return to normal. Should an increase in AST or ALT of 3 X ULN or greater persist, withdrawal of therapy with VYTORIN is recommended.</p>
<p>VYTORIN should be used with caution in patients who consume substantial quantities of alcohol and/or have a past history of liver disease. Active liver diseases or unexplained persistent transaminase elevations are contraindications to the use of VYTORIN.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_01b37490-d8c9-4725-b1be-157b86f9d57f"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Due to the unknown effects of the increased exposure to ezetimibe in patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, VYTORIN is not recommended in these patients. <span class="Italics">[See <a href="#i4i_pharmacokinetics_id_54aca0d2-b6db-489e-9580-e37ab482aec5">Clinical Pharmacology (12.3)</a>.]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_c4385181-675d-4952-a526-817032b43a50"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed in greater detail in other sections of the label:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> and <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> <span class="Italics">[see <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a>]</span>
</li>
<li>Liver enzyme abnormalities <span class="Italics">[see <a href="#i4i_section_id_8ed6c1e8-7476-4ac3-8f7d-bfa4f3fc1ca0">Warnings and Precautions (5.2)</a>]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f9bd7b74-9faf-41ee-9c69-df371172df46"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First"><span class="Bold"><span class="Italics">VYTORIN</span></span></p>
<p>Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p>
<p><br>In the VYTORIN (ezetimibe/simvastatin) placebo-controlled clinical trials database of 1420Â patients (age range 20-83Â years, 52%Â women, 87%Â Caucasians, 3%Â Blacks, 5%Â Hispanics, 3%Â Asians) with a median treatment duration of 27Â weeks, 5%Â of patients on VYTORIN and 2.2% of patients on placebo discontinued due to adverse reactions.</p>
<p>The most common adverse reactions in the group treated with VYTORIN that led to treatment discontinuation and occurred at a rate greater than placebo were:</p>
<ul>
<li>Increased ALT (0.9%)</li>
<li><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span> (0.6%)</li>
<li>Increased AST (0.4%)</li>
<li><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span> (0.4%)</li>
</ul>
<p>The most commonly reported adverse reactions (incidence â‰¥2% and greater than placebo) in controlled clinical trials were: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (5.8%), increased ALT (3.7%), <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> (3.6%), <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span> (3.6%), and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (2.8%).</p>
<p>VYTORIN has been evaluated for safety in more than 10,189Â patients in clinical trials.</p>
<p>TableÂ 2 summarizes the frequency of clinical adverse reactions reported in â‰¥2% of patients treated with VYTORIN (n=1420) and at an incidence greater than placebo, regardless of causality assessment, from four placebo-controlled trials.</p>
<a name="id_aa631aa3-342a-419f-9e7f-4ae38f106ade"></a><table width="726.000">
<caption><span>Table 2<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a>: Clinical Adverse Reactions Occurring in â‰¥2% of Patients Treated with VYTORIN and at an Incidence Greater than Placebo, Regardless of Causality</span></caption>
<col width="39.4%">
<col width="15.2%">
<col width="15.2%">
<col width="15.2%">
<col width="15.2%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="middle">Body System/Organ Class<br>Adverse Reaction </td>
<td class="Botrule" align="center" valign="bottom">Placebo<br>(%)<br>n=371</td>
<td class="Botrule" align="center" valign="bottom">Ezetimibe<br>10Â mg<br>(%)<br>n=302</td>
<td class="Botrule" align="center" valign="bottom">Simvastatin<a name="footnote-reference-6" href="#footnote-6" class="Sup">â€ </a><br>(%)<br>n=1234</td>
<td class="Botrule" align="center" valign="bottom">VYTORIN<a href="#footnote-6" class="Sup">â€ </a><br>(%)<br>n=1420</td>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Includes two placebo-controlled combination studies in which the active ingredients equivalent to VYTORIN were coadministered and two placebo-controlled studies in which VYTORIN was administered.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">â€ </a></dt>
<dd>All doses.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top"><span class="Italics">Body as a whole â€“ general disorders</span></td>
<td class="Toprule" align="center" valign="top"></td>
<td class="Toprule" align="center" valign="top"></td>
<td class="Toprule" align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center" valign="top">5.4</td>
<td align="center" valign="top">6.0</td>
<td align="center" valign="top">5.9</td>
<td align="center" valign="top">5.8</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Gastrointestinal system disorders</span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center" valign="top">2.2</td>
<td align="center" valign="top">5.0</td>
<td align="center" valign="top">3.7</td>
<td align="center" valign="top">2.8</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></td>
<td align="center" valign="top">0.8</td>
<td align="center" valign="top">1.0</td>
<td align="center" valign="top">1.9</td>
<td align="center" valign="top">2.3</td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td align="center" valign="top">2.7</td>
<td align="center" valign="top">5.0</td>
<td align="center" valign="top">5.0</td>
<td align="center" valign="top">3.6</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td align="center" valign="top">2.4</td>
<td align="center" valign="top">2.3</td>
<td align="center" valign="top">2.6</td>
<td align="center" valign="top">3.6</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td class="Botrule" align="center" valign="top">1.3</td>
<td class="Botrule" align="center" valign="top">3.0</td>
<td class="Botrule" align="center" valign="top">2.0</td>
<td class="Botrule" align="center" valign="top">2.3</td>
</tr>
</tbody>
</table>
<p><span class="Italics"><span class="Bold">Ezetimibe</span></span></p>
<p>Other adverse reactions reported with ezetimibe in placebo-controlled studies, regardless of causality assessment: <span class="Italics">Musculoskeletal system disorders:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>; <span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span>:</span> <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>; <span class="Italics">Body as a whole â€“ general disorders:</span> <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>.</p>
<p><span class="Italics"><span class="Bold">Simvastatin</span></span></p>
<p>Other adverse reactions reported with simvastatin in placebo-controlled clinical studies, regardless of causality assessment: <span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>; <span class="Italics">Ear and labyrinth disorders:</span> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>;<span class="Italics"> <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>; <span class="Italics">Skin and subcutaneous tissue disorders:</span> <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; <span class="Italics"><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus; <span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span>:</span> <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>; <span class="Italics">Body as a whole â€“ general disorders:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>/<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>; <span class="Italics">Psychiatric disorders:</span> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.</p>
<p><span class="Bold">Laboratory Tests</span></p>
<p>Marked persistent increases of hepatic serum transaminases have been noted <span class="Italics">[see <a href="#i4i_section_id_8ed6c1e8-7476-4ac3-8f7d-bfa4f3fc1ca0">Warnings and Precautions (5.2)</a>]</span>. Elevated alkaline phosphatase and Î³-glutamyl transpeptidase have been reported. About 5% of patients taking simvastatin had elevations of CK levels of 3 or more times the normal value on one or more occasions. This was attributable to the noncardiac fraction of CK <span class="Italics">[see <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_144b0df7-7c0e-4544-9b72-eade599d6274"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-Marketing Experience</h2>
<p class="First">Because the below reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>The following adverse reactions have been reported in post-marketing experience for VYTORIN or ezetimibe or simvastatin: <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>; <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>; <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>; a variety of skin changes (e.g., <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span>, discoloration, dryness of skin/mucous membranes, changes to hair/nails); <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>; <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>; <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>; <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>; <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>; <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>; <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>; <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>; <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>; <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span>; <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> <span class="Italics">[see <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a>]</span>; <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>/<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>; <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>; <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span>; <span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span>; <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>; elevations in liver transaminases; elevated creatine phosphokinase.</p>
<p><br><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> have been reported.</p>
<p>In addition, an apparent <span class="product-label-link" type="condition" conceptid="45765791" conceptname="Drug reaction with eosinophilia and systemic symptoms">hypersensitivity syndrome</span> has been reported rarely that has included one or more of the following features: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, lupus erythematous-like syndrome, <span class="product-label-link" type="condition" conceptid="255348" conceptname="Polymyalgia rheumatica">polymyalgia rheumatica</span>, <span class="product-label-link" type="condition" conceptid="80182" conceptname="Dermatomyositis">dermatomyositis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, positive ANA, ESR increase, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_acfc6456-bb28-460c-894d-cb2af80b4e02"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"><span class="Italics">[See <a href="#i4i_pharmacokinetics_id_54aca0d2-b6db-489e-9580-e37ab482aec5">Clinical Pharmacology (12.3)</a>.]</span></p>
<p><span class="Italics">VYTORIN</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a38e88d3-256e-407c-ac33-448a99fc7a64"></a><a name="section-7.1"></a><p></p>
<h2>7.1 CYP3A4 Interactions</h2>
<p class="First">The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is increased by reducing the elimination of the simvastatin component of VYTORIN. Hence when VYTORIN is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, particularly with higher doses of VYTORIN. <span class="Italics">[See <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a> and <a href="#i4i_pharmacokinetics_id_54aca0d2-b6db-489e-9580-e37ab482aec5">Clinical Pharmacology (12.3)</a>.]</span></p>
<p><span class="Italics">Itraconazole, ketoconazole, and other antifungal azoles</span></p>
<p><span class="Italics">Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin</span></p>
<p><span class="Italics">HIV protease inhibitors</span></p>
<p><span class="Italics">Antidepressant nefazodone</span></p>
<p><span class="Italics">Grapefruit juice in large quantities (&gt;1Â quart daily)</span></p>
<p>Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk. If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with VYTORIN should be suspended during the course of treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b395b70f-0d19-4d5c-8d61-55033f3eeb9d"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Lipid-Lowering Drugs That Can Cause <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> When Given Alone</h2>
<p class="First">The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is increased by gemfibrozil and to a lesser extent by other fibrates <span class="Italics">[see <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a0181393-2d82-4d35-bdb7-b15176640029"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Amiodarone, Verapamil, or Diltiazem</h2>
<p class="First">The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> is increased by concomitant administration of amiodarone, verapamil, or diltiazem with higher doses of VYTORIN <span class="Italics">[see <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c92a1453-1eea-45e1-aeea-e48e4951eed3"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Niacin</h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been observed with simvastatin coadministered with lipid-modifying doses (â‰¥1Â g/day niacin) of niacin-containing products. In particular, caution should be used when treating Chinese patients with VYTORIN coadministered with lipid-modifying doses of niacin-containing products. Because the risk for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is dose-related, Chinese patients should not receive VYTORIN 10/80 mg coadministered with lipid-modifying doses of niacin-containing products. <span class="Italics">[See <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_da6c7251-4498-439b-aa1e-1c443a7e1c14"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Cholestyramine</h2>
<p class="First">Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%. The incremental LDL-C reduction due to adding VYTORIN to cholestyramine may be reduced by this interaction.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0f2702c7-2df5-4904-a0b4-43eec959f819"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Cyclosporine or Danazol</h2>
<p class="First">The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of VYTORIN <span class="Italics">[see <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a> and <a href="#i4i_pharmacokinetics_id_54aca0d2-b6db-489e-9580-e37ab482aec5">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>Caution should be exercised when using VYTORIN and cyclosporine concomitantly due to increased exposure to both ezetimibe and cyclosporine <span class="Italics">[see <a href="#i4i_section_id_b26a6a53-5c8d-4643-860c-d873eb4c4c2d">Dosage and Administration (2.7)</a>]</span>. Cyclosporine concentrations should be monitored in patients receiving VYTORIN and cyclosporine <span class="Italics">[see <a href="#i4i_pharmacokinetics_id_54aca0d2-b6db-489e-9580-e37ab482aec5">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>The degree of increase in ezetimibe exposure may be greater in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. In patients treated with cyclosporine, the potential effects of the increased exposure to ezetimibe from concomitant use should be carefully weighed against the benefits of alterations in lipid levels provided by ezetimibe. <span class="Italics">[See <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a> and <a href="#i4i_pharmacokinetics_id_54aca0d2-b6db-489e-9580-e37ab482aec5">Clinical Pharmacology (12.3)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1990b319-f635-4269-982f-09ff939c239c"></a><a name="section-7.7"></a><p></p>
<h2>7.7 Digoxin</h2>
<p class="First">In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in plasma digoxin concentrations. Patients taking digoxin should be monitored appropriately when VYTORIN is initiated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d14fc525-3963-4234-a3e6-a76b1b33cfd0"></a><a name="section-7.8"></a><p></p>
<h2>7.8 Fibrates</h2>
<p class="First">The safety and effectiveness of VYTORIN administered with fibrates have not been established.</p>
<p>Fibrates may increase <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> excretion into the bile, leading to <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span>. In a preclinical study in dogs, ezetimibe increased <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in the gallbladder bile <span class="Italics">[see <a href="#i4i_animal_pharmacology_id_5ebf0241-a904-4107-a612-a030e0975e46">Animal Toxicology and/or Pharmacology (13.2)</a>]</span>. Coadministration of VYTORIN with fibrates is not recommended until use in patients is studied. <span class="Italics">[See <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ad784484-4573-42ce-be7d-7a37ce89b061"></a><a name="section-7.9"></a><p></p>
<h2>7.9 Coumarin Anticoagulants</h2>
<p class="First">Simvastatin 20-40Â mg/day modestly potentiated the effect of coumarin anticoagulants: the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in a normal volunteer study and in a hypercholesterolemic patient study, respectively. With other statins, clinically evident <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and/or increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time has been reported in a few patients taking coumarin anticoagulants concomitantly. In such patients, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time should be determined before starting VYTORIN and frequently enough during early therapy to ensure that no significant alteration of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time occurs. Once a stable <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time has been documented, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants. If the dose of VYTORIN is changed or discontinued, the same procedure should be repeated. Simvastatin therapy has not been associated with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or with changes in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients not taking anticoagulants.</p>
<p>Concomitant administration of ezetimibe (10Â mg once daily) had no significant effect on bioavailability of warfarin and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in a study of twelve healthy adult males. There have been post-marketing reports of increased INR in patients who had ezetimibe added to warfarin. Most of these patients were also on other medications.</p>
<p>The effect of VYTORIN on the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time has not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_106d2f36-67ea-4092-bc03-d76c581a7a32"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_1d00559e-220c-4a6e-bf52-2ccf7690635f"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy CategoryÂ X.</span></p>
<p><span class="Italics">[See <a href="#i4i_contraindications_id_9e30296b-de48-4816-9c39-6a8ec2edca07">Contraindications (4)</a>.]</span></p>
<p><span class="Italics">VYTORIN</span></p>
<p>VYTORIN is contraindicated in women who are or may become pregnant. Lipid-lowering drugs offer no benefit during pregnancy, because <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> derivatives are needed for normal fetal development. <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> is a chronic process, and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> therapy. There are no adequate and well-controlled studies of VYTORIN use during pregnancy; however, there are rare reports of congenital anomalies in infants exposed to statins <span class="Italics">in utero</span>. Animal reproduction studies of simvastatin in rats and rabbits showed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. Serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides increase during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span>, and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> derivatives are essential for fetal development. Because statins, such as simvastatin, decrease <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis and possibly the synthesis of other biologically active substances derived from <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, VYTORIN may cause fetal harm when administered to a pregnant woman. If VYTORIN is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p>Women of childbearing potential, who require VYTORIN treatment for a lipid disorder, should be advised to use effective contraception. For women trying to conceive, discontinuation of VYTORIN should be considered. If pregnancy occurs, VYTORIN should be immediately discontinued.</p>
<p><span class="Italics">Ezetimibe</span></p>
<p>In oral (gavage) embryo-fetal development studies of ezetimibe conducted in rats and rabbits during organogenesis, there was no evidence of embryolethal effects at the doses tested (250, 500, 1000Â mg/kg/day). In rats, increased incidences of common fetal skeletal findings (extra pair of thoracic ribs, unossified cervical vertebral centra, shortened ribs) were observed at 1000Â mg/kg/day (~10Â times the human exposure at 10Â mg daily based on AUC<span class="Sub">0-24hr</span> for total ezetimibe). In rabbits treated with ezetimibe, an increased incidence of extra thoracic ribs was observed at 1000Â mg/kg/day (150Â times the human exposure at 10Â mg daily based on AUC<span class="Sub">0-24hr</span> for total ezetimibe). Ezetimibe crossed the placenta when pregnant rats and rabbits were given multiple oral doses.</p>
<p>Multiple-dose studies of ezetimibe coadministered with statins in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. Reproductive findings occur at lower doses in coadministration therapy compared to monotherapy.</p>
<p><span class="Italics">Simvastatin</span></p>
<p>Simvastatin was not teratogenic in rats or rabbits at doses (25, 10Â mg/kg/day, respectively) that resulted in 3Â times the human exposure based on mg/m<span class="Sup">2</span> surface area. However, in studies with another structurally-related statin, skeletal malformations were observed in rats and mice.</p>
<p>There are rare reports of congenital anomalies following intrauterine exposure to statins. In a review<a name="footnote-reference-7" href="#footnote-7" class="Sup">1</a> of approximately 100Â prospectively followed pregnancies in women exposed to simvastatin or another structurally-related statin, the incidences of congenital anomalies, <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span> and <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span>/<span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> did not exceed what would be expected in the general population. The number of cases is adequate only to exclude a 3- to 4-fold increase in congenital anomalies over the background incidence. In 89% of the prospectively followed pregnancies, drug treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">1</a></dt>
<dd><p class="First">Manson, J.M., Freyssinges, C., Ducrocq, M.B., Stephenson, W.P., Postmarketing Surveillance of Lovastatin and Simvastatin Exposure During Pregnancy, <span class="Italics">Reproductive Toxicology</span>, 10(6):439-446, 1996.</p></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_a37c37f4-681b-4fa4-a794-fd895cf1f36e"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether simvastatin is excreted in human milk. Because a small amount of another drug in this class is excreted in human milk and because of the potential for serious adverse reactions in nursing infants, women taking simvastatin should not nurse their infants. A decision should be made whether to discontinue nursing or discontinue drug, taking into account the importance of the drug to the mother <span class="Italics">[see <a href="#i4i_contraindications_id_9e30296b-de48-4816-9c39-6a8ec2edca07">Contraindications (4)</a>]</span>.</p>
<p>In rat studies, exposure to ezetimibe in nursing pups was up to half of that observed in maternal plasma. It is not known whether ezetimibe or simvastatin are excreted into human breast milk. Because a small amount of another drug in the same class as simvastatin is excreted in human milk and because of the potential for serious adverse reactions in nursing infants, women who are nursing should not take VYTORIN <span class="Italics">[see <a href="#i4i_contraindications_id_9e30296b-de48-4816-9c39-6a8ec2edca07">Contraindications (4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_87696b87-e687-448b-b9e8-b7fa95dff679"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The effects of ezetimibe coadministered with simvastatin (n=126) compared to simvastatin monotherapy (n=122) have been evaluated in adolescent boys and girls with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> (HeFH). In a multicenter, double-blind, controlled study followed by an open-label phase, 142Â boys and 106Â postmenarchal girls, 10 to 17Â years of age (mean age 14.2Â years, 43%Â females, 82%Â Caucasians, 4%Â Asian, 2%Â Blacks, 13%Â multi-racial) with HeFH were randomized to receive either ezetimibe coadministered with simvastatin or simvastatin monotherapy. Inclusion in the study required 1) a baseline LDL-C level between 160 and 400Â mg/dL and 2) a medical history and clinical presentation consistent with HeFH. The mean baseline LDL-C value was 225Â mg/dL (range: 161-351Â mg/dL) in the ezetimibe coadministered with simvastatin group compared to 219Â mg/dL (range: 149-336Â mg/dL) in the simvastatin monotherapy group. The patients received coadministered ezetimibe and simvastatin (10Â mg, 20Â mg, or 40Â mg) or simvastatin monotherapy (10Â mg, 20Â mg, or 40Â mg) for 6Â weeks, coadministered ezetimibe and 40Â mg simvastatin or 40Â mg simvastatin monotherapy for the next 27Â weeks, and open-label coadministered ezetimibe and simvastatin (10Â mg, 20Â mg, or 40Â mg) for 20Â weeks thereafter.</p>
<p>The results of the study at WeekÂ 6 are summarized in Table 3. Results at WeekÂ 33 were consistent with those at WeekÂ 6.</p>
<a name="id_3d56dec0-51a5-497d-8e8d-bb6ab085d70a"></a><table width="751.000">
<caption><span>Table 3: Mean Percent Difference at Week 6 Between the Pooled Ezetimibe Coadministered with Simvastatin Group and the Pooled Simvastatin Monotherapy Group in Adolescent Patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span></span></caption>
<col width="25.7%">
<col width="12.0%">
<col width="14.4%">
<col width="11.2%">
<col width="12.0%">
<col width="11.2%">
<col width="13.6%">
<thead><tr class="First Last">
<td class="Botrule" align="center" valign="bottom"></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Total-C</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">LDL-C</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span></span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Non-HDL-C</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">TG<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a></span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">HDL-C</span></td>
</tr></thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>For triglycerides, median % change from baseline</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="center" valign="middle">Mean percent difference between treatment groups</td>
<td class="Botrule" align="center" valign="middle">-12%</td>
<td class="Botrule" align="center" valign="middle">-15%</td>
<td class="Botrule" align="center" valign="middle">-12%</td>
<td class="Botrule" align="center" valign="middle">-14%</td>
<td class="Botrule" align="center" valign="middle">-2%</td>
<td class="Botrule" align="center" valign="middle">+0.1%</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="middle">95% Confidence Interval</td>
<td class="Botrule" align="center" valign="middle">(-15%, -9%)</td>
<td class="Botrule" align="center" valign="middle">(-18%, -12%)</td>
<td class="Botrule" align="center" valign="middle">(-15%, -9%)</td>
<td class="Botrule" align="center" valign="middle">(-17%, -11%)</td>
<td class="Botrule" align="center" valign="middle">(-9, +4)</td>
<td class="Botrule" align="center" valign="middle">(-3, +3)</td>
</tr>
</tbody>
</table>
<p>From the start of the trial to the end of WeekÂ 33, discontinuations due to an adverse reaction occurred in 7Â (6%)Â patients in the ezetimibe coadministered with simvastatin group and in 2Â (2%)Â patients in the simvastatin monotherapy group.</p>
<p>During the trial, hepatic transaminase elevations (two consecutive measurements for ALT and/or AST â‰¥3 X ULN) occurred in fourÂ (3%)Â individuals in the ezetimibe coadministered with simvastatin group and in twoÂ (2%)Â individuals in the simvastatin monotherapy group. Elevations of CPK (â‰¥10 X ULN) occurred in two (2%) individuals in the ezetimibe coadministered with simvastatin group and in zero individuals in the simvastatin monotherapy group.</p>
<p>In this limited controlled study, there was no significant effect on growth or sexual maturation in the adolescent boys or girls, or on menstrual cycle length in girls.</p>
<p>Coadministration of ezetimibe with simvastatin at doses greater than 40Â mg/day has not been studied in adolescents. Also, VYTORIN has not been studied in patients younger than 10Â years of age or in pre-menarchal girls.</p>
<p><br><span class="Italics">Ezetimibe</span></p>
<p>Based on total ezetimibe (ezetimibe + ezetimibe-glucuronide) there are no pharmacokinetic differences between adolescents and adults. Pharmacokinetic data in the pediatric population &lt;10Â years of age are not available.</p>
<p><br><span class="Italics">Simvastatin</span></p>
<p>The pharmacokinetics of simvastatin has not been studied in the pediatric population.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_a62fff98-a7ad-4f1e-8b82-4b3cc3b71988"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the 10,189 patients who received VYTORIN in clinical studies, 3242 (32%) were 65 and older (this included 844 (8%) who were 75 and older). No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients but greater sensitivity of some older individuals cannot be ruled out. Since advanced age (â‰¥65Â years) is a predisposing factor for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, VYTORIN should be prescribed with caution in the elderly. <span class="Italics">[See <a href="#i4i_pharmacokinetics_id_54aca0d2-b6db-489e-9580-e37ab482aec5">Clinical Pharmacology (12.3)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_181c96b0-b591-4845-95e9-0478f4d55f3a"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Caution should be exercised when VYTORIN is administered to patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. <span class="Italics">[See <a href="#i4i_section_id_dbf7935b-8836-43e8-9f19-89ff556d10d9">Dosage and Administration (2.4)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5373d07f-c518-406c-818e-4718b7b0eb67"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">VYTORIN is contraindicated in patients with active liver disease or unexplained persistent elevations of hepatic transaminases. VYTORIN is not recommended in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. <span class="Italics">[See <a href="#i4i_contraindications_id_9e30296b-de48-4816-9c39-6a8ec2edca07">Contraindications (4)</a> and <a href="#i4i_section_id_8ed6c1e8-7476-4ac3-8f7d-bfa4f3fc1ca0">Warnings and Precautions (5.2)</a>.]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_a17198ef-d9f5-41f5-9233-783e750c76e2"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"><span class="Italics">VYTORIN</span></p>
<p>No specific treatment of overdosage with VYTORIN can be recommended. In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, symptomatic and supportive measures should be employed.</p>
<p><span class="Italics">Ezetimibe</span></p>
<p>In clinical studies, administration of ezetimibe, 50Â mg/day to 15Â healthy subjects for up to 14Â days, or 40Â mg/day to 18Â patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> for up to 56Â days, was generally well tolerated. </p>
<p>A few cases of overdosage have been reported; most have not been associated with adverse experiences. Reported adverse experiences have not been serious. </p>
<p><span class="Italics">Simvastatin</span></p>
<p>Significant lethality was observed in mice after a single oral dose of 9Â g/m<span class="Sup">2</span>. No evidence of lethality was observed in rats or dogs treated with doses of 30 and 100Â g/m<span class="Sup">2</span>, respectively. No specific diagnostic signs were observed in rodents. At these doses the only signs seen in dogs were <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> and mucoid stools.</p>
<p>A few cases of overdosage with simvastatin have been reported; the maximum dose taken was 3.6Â g. All patients recovered without sequelae.</p>
<p>The dialyzability of simvastatin and its metabolites in man is not known at present.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_a955c0f3-2352-499f-9853-d792c12b0f45"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">VYTORIN contains ezetimibe, a selective inhibitor of intestinal <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and related phytosterol absorption, and simvastatin, an HMG-CoA reductase inhibitor.</p>
<p>The chemical name of ezetimibe is 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone. The empirical formula is C<span class="Sub">24</span>H<span class="Sub">21</span>F<span class="Sub">2</span>NO<span class="Sub">3</span> and its molecular weight is 409.4. </p>
<p>Ezetimibe is a white, crystalline powder that is freely to very soluble in ethanol, methanol, and acetone and practically insoluble in water. Its structural formula is:</p>
<div class="Figure"><img alt="image of ezetimibe structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=65e1c3ae-a462-4345-8a28-c7d2c0388af8&amp;name=65e1c3ae-a462-4345-8a28-c7d2c0388af8-01.jpg"></div>
<p>Simvastatin, an inactive lactone, is hydrolyzed to the corresponding Î²-hydroxyacid form, which is an inhibitor of HMGCoA reductase. Simvastatin is butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2<span class="Italics">H</span>-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1<span class="Italics">S</span>-[1Î±,3Î±,7Î²,8Î²(2<span class="Italics">S*</span>,4<span class="Italics">S*</span>),-8aÎ²]]. The empirical formula of simvastatin is C<span class="Sub">25</span>H<span class="Sub">38</span>O<span class="Sub">5</span> and its molecular weight is 418.57. </p>
<p>Simvastatin is a white to off-white, nonhygroscopic, crystalline powder that is practically insoluble in water and freely soluble in chloroform, methanol and ethanol. Its structural formula is:</p>
<div class="Figure"><img alt="image of simvastatin structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=65e1c3ae-a462-4345-8a28-c7d2c0388af8&amp;name=65e1c3ae-a462-4345-8a28-c7d2c0388af8-02.jpg"></div>
<p>VYTORINÂ is available for oral use as tablets containing 10Â mg of ezetimibe, and 10Â mg of simvastatin (VYTORINÂ 10/10), 20Â mg of simvastatin (VYTORIN 10/20), 40Â mg of simvastatin (VYTORIN 10/40), or 80Â mg of simvastatin (VYTORIN 10/80). Each tablet contains the following inactive ingredients: butylated hydroxyanisole NF, citric acid monohydrate USP, croscarmellose sodium NF, hypromellose USP, lactose monohydrate NF, magnesium stearate NF, microcrystalline cellulose NF, and propyl gallate NF.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_9885988c-6f5c-42b8-9761-ceb3bf16dd2d"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_e2d9c634-1971-42cd-91ea-a708e0973eee"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First"><span class="Italics">VYTORIN</span></p>
<p>Plasma <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> is derived from intestinal absorption and endogenous synthesis. VYTORIN contains ezetimibe and simvastatin, two lipid-lowering compounds with complementary mechanisms of action. VYTORIN reduces elevated total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, TG, and non-HDL-C, and increases HDL-C through dual inhibition of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> absorption and synthesis.</p>
<p><br><span class="Italics">Ezetimibe</span></p>
<p>Ezetimibe reduces blood <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> by inhibiting the absorption of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> by the small intestine. The molecular target of ezetimibe has been shown to be the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and phytosterols. In a 2-week clinical study in 18Â hypercholesterolemic patients, ezetimibe inhibited intestinal <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> absorption by 54%, compared with placebo. Ezetimibe had no clinically meaningful effect on the plasma concentrations of the fat-soluble vitamins A, D, and E and did not impair adrenocortical steroid hormone production.</p>
<p>Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, leading to a decrease in the delivery of intestinal <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> to the liver. This causes a reduction of hepatic <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> stores and an increase in clearance of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> from the blood; this distinct mechanism is complementary to that of statins <span class="Italics">[see <a href="#i4i_clinical_studies_id_1f4b76ad-013f-408f-b639-d9a1b5e9ab6f">Clinical Studies (14)</a>]</span>.</p>
<p><br><span class="Italics">Simvastatin</span></p>
<p>Simvastatin is a prodrug and is hydrolyzed to its active Î²-hydroxyacid form, simvastatin acid, after administration. Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. In addition, simvastatin reduces very-low-density lipoproteins (VLDL) and TG and increases HDL-C.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_1f4be6f4-e09d-4604-a541-bb041b82b6d1"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Clinical studies have demonstrated that elevated levels of total-C, LDL-C and ApoÂ B, the major protein constituent of LDL, promote human <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>. In addition, decreased levels of HDL-C are associated with the development of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>. Epidemiologic studies have established that cardiovascular morbidity and mortality vary directly with the level of total-C and LDL-C and inversely with the level of HDL-C. Like LDL, <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-enriched triglyceride-rich lipoproteins, including VLDL, intermediate-density lipoproteins (IDL), and remnants, can also promote <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>. The independent effect of raising HDL-C or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_54aca0d2-b6db-489e-9580-e37ab482aec5"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The results of a bioequivalence study in healthy subjects demonstrated that the VYTORIN (ezetimibe/simvastatin) 10Â mg/10Â mg to 10Â mg/80Â mg combination tablets are bioequivalent to coadministration of corresponding doses of ezetimibe (ZETIA<span class="Sup">Â®</span>) and simvastatin (ZOCOR<span class="Sup">Â®</span>) as individual tablets.</p>
<p><span class="Italics"><span class="Bold">Absorption</span></span></p>
<p><span class="Italics">Ezetimibe</span></p>
<p>After oral administration, ezetimibe is absorbed and extensively conjugated to a pharmacologically active phenolic glucuronide (ezetimibe-glucuronide).</p>
<p><br><span class="Italics">Simvastatin</span></p>
<p>The availability of the Î²-hydroxyacid to the systemic circulation following an oral dose of simvastatin was found to be less than 5% of the dose, consistent with extensive hepatic first-pass extraction.</p>
<p><span class="Italics"><span class="Bold">Effect of Food on Oral Absorption</span></span></p>
<p><span class="Italics">Ezetimibe</span></p>
<p>Concomitant food administration (high-fat or non-fat meals) had no effect on the extent of absorption of ezetimibe when administered as 10-mg tablets. The C<span class="Sub">max</span> value of ezetimibe was increased by 38% with consumption of high-fat meals.</p>
<p><br><span class="Italics">Simvastatin</span></p>
<p>Relative to the fasting state, the plasma profiles of both active and total inhibitors of HMG-CoA reductase were not affected when simvastatin was administered immediately before an American Heart Association recommended low-fat meal.</p>
<p><span class="Italics"><span class="Bold">Distribution</span></span></p>
<p><span class="Italics">Ezetimibe</span></p>
<p>Ezetimibe and ezetimibe-glucuronide are highly bound (&gt;90%) to human plasma proteins.</p>
<p><span class="Italics">Simvastatin</span></p>
<p>Both simvastatin and its Î²-hydroxyacid metabolite are highly bound (approximately 95%) to human plasma proteins. When radiolabeled simvastatin was administered to rats, simvastatin-derived radioactivity crossed the blood-brain barrier.</p>
<p><span class="Italics"><span class="Bold">Metabolism and Excretion</span></span></p>
<p><span class="Italics">Ezetimibe</span></p>
<p>Ezetimibe is primarily metabolized in the small intestine and liver via glucuronide conjugation with subsequent biliary and renal excretion. Minimal oxidative metabolism has been observed in all species evaluated. </p>
<p>In humans, ezetimibe is rapidly metabolized to ezetimibe-glucuronide. Ezetimibe and ezetimibe-glucuronide are the major drug-derived compounds detected in plasma, constituting approximately 10 to 20% and 80 to 90% of the total drug in plasma, respectively. Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22Â hours for both ezetimibe and ezetimibe-glucuronide. Plasma concentration-time profiles exhibit multiple peaks, suggesting enterohepatic recycling. </p>
<p>Following oral administration of <span class="Sup">14</span>C-ezetimibe (20Â mg) to human subjects, total ezetimibe (ezetimibe + ezetimibe-glucuronide) accounted for approximately 93% of the total radioactivity in plasma. After 48Â hours, there were no detectable levels of radioactivity in the plasma.</p>
<p>Approximately 78% and 11% of the administered radioactivity were recovered in the feces and urine, respectively, over a 10-day collection period. Ezetimibe was the major component in feces and accounted for 69% of the administered dose, while ezetimibe-glucuronide was the major component in urine and accounted for 9% of the administered dose.</p>
<p><span class="Italics">Simvastatin</span></p>
<p>Simvastatin is a lactone that is readily hydrolyzed <span class="Italics">inÂ vivo</span> to the corresponding Î²-hydroxyacid, a potent inhibitor of HMG-CoA reductase. Inhibition of HMG-CoA reductase is a basis for an assay in pharmacokinetic studies of the Î²-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin. The major active metabolites of simvastatin present in human plasma are the Î²-hydroxyacid of simvastatin and its 6â€²-hydroxy, 6â€²-hydroxymethyl, and 6â€²-exomethylene derivatives.</p>
<p>Following an oral dose of <span class="Sup">14</span>C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces. Plasma concentrations of total radioactivity (simvastatin plus <span class="Sup">14</span>C-metabolites) peaked at 4Â hours and declined rapidly to about 10% of peak by 12Â hours postdose.</p>
<p><span class="Italics"><span class="Bold">Specific Populations</span></span></p>
<p><span class="Italics"><span class="Bold">Geriatric Patients</span></span></p>
<p><span class="Italics">Ezetimibe</span></p>
<p>In a multiple-dose study with ezetimibe given 10Â mg once daily for 10Â days, plasma concentrations for total ezetimibe were about 2-fold higher in older (â‰¥65 years) healthy subjects compared to younger subjects.</p>
<p><br><span class="Italics">Simvastatin</span></p>
<p>In a study including 16Â elderly patients between 70 and 78Â years of age who received simvastatin 40Â mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18Â patients between 18-30Â years of age.</p>
<p><span class="Italics"><span class="Bold">Pediatric Patients:</span> [See <a href="#i4i_pediatric_use_id_87696b87-e687-448b-b9e8-b7fa95dff679">Pediatric Use (8.4)</a>.]</span></p>
<p><span class="Italics"><span class="Bold">Gender</span></span></p>
<p><span class="Italics">Ezetimibe</span></p>
<p>In a multiple-dose study with ezetimibe given 10Â mg once daily for 10Â days, plasma concentrations for total ezetimibe were slightly higher (&lt;20%) in women than in men.</p>
<p><span class="Italics"><span class="Bold">Race</span></span></p>
<p><span class="Italics">Ezetimibe</span></p>
<p>Based on a meta-analysis of multiple-dose pharmacokinetic studies, there were no pharmacokinetic differences between Black and Caucasian subjects. Studies in Asian subjects indicated that the pharmacokinetics of ezetimibe was similar to those seen in Caucasian subjects.</p>
<p><span class="Italics"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span></p>
<p><span class="Italics">Ezetimibe</span></p>
<p>After a single 10-mg dose of ezetimibe, the mean exposure (based on area under the curve [AUC]) to total ezetimibe was increased approximately 1.7-fold in patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score 5 to 6), compared to healthy subjects. The mean AUC values for total ezetimibe and ezetimibe increased approximately 3- to 4-fold and 5- to 6-fold, respectively, in patients with moderate (Child-Pugh score 7 to 9) or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score 10 to 15). In a 14-day, multiple-dose study (10Â mg daily) in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, the mean AUC for total ezetimibe and ezetimibe increased approximately 4-fold compared to healthy subjects.</p>
<p><span class="Italics"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></p>
<p><span class="Italics">Ezetimibe</span></p>
<p>After a single 10-mg dose of ezetimibe in patients with severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (n=8; mean CrClÂ â‰¤30Â mL/min/1.73Â m<span class="Sup">2</span>), the mean AUC for total ezetimibe and ezetimibe increased approximately 1.5-fold, compared to healthy subjects (n=9).</p>
<p><br><span class="Italics">Simvastatin</span></p>
<p>Pharmacokinetic studies with another statin having a similar principal route of elimination to that of simvastatin have suggested that for a given dose level higher systemic exposure may be achieved in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (as measured by creatinine clearance).</p>
<p><span class="Italics"><span class="Bold">Drug Interactions [See also <a href="#i4i_interactions_id_acfc6456-bb28-460c-894d-cb2af80b4e02">Drug Interactions (7)</a>.]</span></span></p>
<p>No clinically significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> was seen when ezetimibe was coadministered with simvastatin. No specific pharmacokinetic drug interaction studies with VYTORIN have been conducted other than the following study with NIASPAN (Niacin extended-release tablets).</p>
<p><span class="Bold">Niacin:</span> The effect of VYTORIN (10/20Â mg daily for 7Â days) on the pharmacokinetics of NIASPAN extended-release tablets (1000Â mg for 2Â days and 2000Â mg for 5Â days following a low-fat breakfast) was studied in healthy subjects. The mean C<span class="Sub">max</span> and AUC of niacin increased 9% and 22%, respectively. The mean C<span class="Sub">max</span> and AUC of nicotinuric acid increased 10% and 19%, respectively (N=13). In the same study, the effect of NIASPAN on the pharmacokinetics of VYTORIN was evaluated (N=15). While concomitant NIASPAN decreased the mean C<span class="Sub">max</span> of total ezetimibe (1%), and simvastatin (2%), it increased the mean C<span class="Sub">max</span> of simvastatin acid (18%). In addition, concomitant NIASPAN increased the mean AUC of total ezetimibe (26%), simvastatin (20%), and simvastatin acid (35%). </p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been observed with simvastatin coadministered with lipid-modifying doses (â‰¥1Â g/day niacin) of niacin-containing products.<span class="Italics"> [See <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a> and <a href="#i4i_section_id_c92a1453-1eea-45e1-aeea-e48e4951eed3">Drug Interactions (7.4)</a>.]</span></p>
<p><span class="Bold">Cytochrome P450:</span> Ezetimibe had no significant effect on a series of probe drugs (caffeine, dextromethorphan, tolbutamide, and IV midazolam) known to be metabolized by cytochrome P450 (1A2, 2D6, 2C8/9 and 3A4) in a â€œcocktailâ€? study of twelve healthy adult males. This indicates that ezetimibe is neither an inhibitor nor an inducer of these cytochrome P450 isozymes, and it is unlikely that ezetimibe will affect the metabolism of drugs that are metabolized by these enzymes.</p>
<p>In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin. This indicates that simvastatin is not an inhibitor of CYP3A4 and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.</p>
<p>Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins. The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.</p>
<p>Simvastatin is a substrate for CYP3A4. Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>. <span class="Italics">[See <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a>; <a href="#i4i_section_id_a38e88d3-256e-407c-ac33-448a99fc7a64">Drug Interactions (7.1)</a>.]</span></p>
<p><br><span class="Italics">Ezetimibe</span></p>
<a name="id_71916012-e054-409f-8f88-6b2c35c64fdb"></a><table width="701.000">
<caption><span>Table 4: Effect of Coadministered Drugs on Total Ezetimibe</span></caption>
<col width="55.6%">
<col width="21.5%">
<col width="22.8%">
<thead>
<tr class="First">
<td class="Toprule" align="center" rowspan="2" valign="top"><span class="Bold">Coadministered Drug and Dosing Regimen</span></td>
<td align="center" colspan="2" valign="top"><span class="Bold">Total Ezetimibe<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a></span></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Change in AUC</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Change in C<span class="Sub">max</span></span></td>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>Based on 10Â mg-dose of ezetimibe</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">â€ </a></dt>
<dd>Post-renal transplant patients with mild impaired or normal renal function. In a different study, a renal transplant patient with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (creatinine clearance of 13.2Â mL/min/1.73Â m<span class="Sup">2</span>) who was receiving multiple medications, including cyclosporine, demonstrated a 12-fold greater exposure to total ezetimibe compared to healthy subjects.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">â€¡</a></dt>
<dd>See 7. Drug Interactions</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">Â§</a></dt>
<dd>Supralox<span class="Sup">Â®</span>, 20Â mL</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">Cyclosporine-stable dose required (75-150Â mg BID)<a name="footnote-reference-10" href="#footnote-10" class="Sup">â€ </a>, <a name="footnote-reference-11" href="#footnote-11" class="Sup">â€¡</a>
</td>
<td class="Botrule" align="center" valign="top">â†‘240%</td>
<td class="Botrule" align="center" valign="top">â†‘290%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Fenofibrate, 200Â mg QD, 14Â days<a href="#footnote-11" class="Sup">â€¡</a>
</td>
<td class="Botrule" align="center" valign="top">â†‘48%</td>
<td class="Botrule" align="center" valign="top">â†‘64%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Gemfibrozil, 600Â mg BID, 7Â days<a href="#footnote-11" class="Sup">â€¡</a>
</td>
<td class="Botrule" align="center" valign="top">â†‘64%</td>
<td class="Botrule" align="center" valign="top">â†‘91%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Cholestyramine, 4Â g BID, 14Â days<a href="#footnote-11" class="Sup">â€¡</a>
</td>
<td class="Botrule" align="center" valign="top">â†“55%</td>
<td class="Botrule" align="center" valign="top">â†“4%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Aluminum &amp; magnesium hydroxide combination antacid, single dose<a name="footnote-reference-12" href="#footnote-12" class="Sup">Â§</a>
</td>
<td class="Botrule" align="center" valign="top">â†“4%</td>
<td class="Botrule" align="center" valign="top">â†“30%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Cimetidine, 400Â mg BID, 7Â days</td>
<td class="Botrule" align="center" valign="top">â†‘6%</td>
<td class="Botrule" align="center" valign="top">â†‘22%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Glipizide, 10Â mg, single dose</td>
<td class="Botrule" align="center" valign="top">â†‘4%</td>
<td class="Botrule" align="center" valign="top">â†“8%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="Bold">Statins</span></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â Lovastatin 20Â mg QD, 7Â days</td>
<td class="Botrule" align="center" valign="top">â†‘9%</td>
<td class="Botrule" align="center" valign="top">â†‘3%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â Pravastatin 20Â mg QD, 14Â days</td>
<td class="Botrule" align="center" valign="top">â†‘7%</td>
<td class="Botrule" align="center" valign="top">â†‘23%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â Atorvastatin 10Â mg QD, 14Â days</td>
<td class="Botrule" align="center" valign="top">â†“2%</td>
<td class="Botrule" align="center" valign="top">â†‘12%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â Rosuvastatin 10Â mg QD, 14Â days</td>
<td class="Botrule" align="center" valign="top">â†‘13%</td>
<td class="Botrule" align="center" valign="top">â†‘18%</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Â Â Â Â Fluvastatin 20Â mg QD, 14Â days</td>
<td class="Botrule" align="center" valign="top">â†“19%</td>
<td class="Botrule" align="center" valign="top">â†‘7%</td>
</tr>
</tbody>
</table>
<a name="id_e7e737c7-639d-4c68-ad7f-5897f9091b78"></a><table width="851.000">
<caption><span>Table 5: Effect of Ezetimibe Coadministration on Systemic Exposure to Other Drugs</span></caption>
<col width="43.6%">
<col width="18.8%">
<col width="20.8%">
<col width="16.8%">
<thead><tr class="First Last">
<td class="Botrule" align="center" valign="top"><span class="Bold">Coadministered Drug and its Dosage Regimen</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">Ezetimibe Dosage Regimen</span></td>
<td class="Botrule" align="center" valign="top">
<p class="First"><span class="Bold">Change in AUC</span></p>
<span class="Bold">of Coadministered Drug</span>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First"><span class="Bold">Change in C<span class="Sub">max</span></span></p>
<span class="Bold">of Coadministered Drug</span>
</td>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-13" href="#footnote-reference-13">*</a></dt>
<dd>See 7. Drug Interactions</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">Warfarin, 25Â mg single dose on DayÂ 7 </td>
<td class="Botrule" align="left" valign="top">10Â mg QD, 11Â days </td>
<td class="Botrule" align="center" valign="top">
<p class="First">â†“2% (R-warfarin)</p>â†“4% (S-warfarin)</td>
<td class="Botrule" align="center" valign="top">
<p class="First">â†‘3% (R-warfarin)</p>â†‘1% (S-warfarin)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Digoxin, 0.5Â mg single dose</td>
<td class="Botrule" align="left" valign="top">10Â mg QD, 8Â days</td>
<td class="Botrule" align="center" valign="top">â†‘2%</td>
<td class="Botrule" align="center" valign="top">â†“7%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Gemfibrozil, 600Â mg BID, 7Â days<a name="footnote-reference-13" href="#footnote-13" class="Sup">*</a>
</td>
<td class="Botrule" align="left" valign="top">10Â mg QD, 7Â days</td>
<td class="Botrule" align="center" valign="top">â†“1%</td>
<td class="Botrule" align="center" valign="top">â†“11%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Ethinyl estradiol &amp; Levonorgestrel<br>QD, 21Â days</td>
<td class="Botrule" align="left" valign="top">10Â mg QD,<br>Days 8-14 of<br>21Â day oral contraceptive cycle</td>
<td class="Botrule" align="center" valign="top">
<p class="First">Ethinyl estradiol</p>
<p>0%</p>
<p>Levonorgestrel</p>0%</td>
<td class="Botrule" align="center" valign="top">
<p class="First">Ethinyl estradiol</p>
<p>â†“9%</p>
<p>Levonorgestrel</p>â†“5%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Glipizide, 10Â mg on DaysÂ 1 and 9</td>
<td class="Botrule" align="left" valign="top">10Â mg QD, DaysÂ 2-9</td>
<td class="Botrule" align="center" valign="top">â†“3%</td>
<td class="Botrule" align="center" valign="top">â†“5%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Fenofibrate, 200Â mg QD, 14Â days<a href="#footnote-13" class="Sup">*</a>
</td>
<td class="Botrule" align="left" valign="top">10Â mg QD, 14Â days</td>
<td class="Botrule" align="center" valign="top">â†‘11%</td>
<td class="Botrule" align="center" valign="top">â†‘7%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Cyclosporine, 100Â mg single dose DayÂ 7<a href="#footnote-13" class="Sup">*</a>
</td>
<td class="Botrule" align="left" valign="top">20Â mg QD, 8Â days</td>
<td class="Botrule" align="center" valign="top">â†‘15%</td>
<td class="Botrule" align="center" valign="top">â†‘10%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="Bold">Statins</span></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â Lovastatin 20Â mg QD, <br>Â Â Â Â 7Â days</td>
<td class="Botrule" align="left" valign="top">10Â mg QD, 7Â days</td>
<td class="Botrule" align="center" valign="top">â†‘19%</td>
<td class="Botrule" align="center" valign="top">â†‘3%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â Pravastatin 20Â mg QD, <br>Â Â Â Â 14Â days</td>
<td class="Botrule" align="left" valign="top">10Â mg QD, 14Â days</td>
<td class="Botrule" align="center" valign="top">â†“20%</td>
<td class="Botrule" align="center" valign="top">â†“24%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â Atorvastatin 10Â mg QD, <br>Â Â Â Â 14Â days</td>
<td class="Botrule" align="left" valign="top">10Â mg QD, 14Â days</td>
<td class="Botrule" align="center" valign="top">â†“4%</td>
<td class="Botrule" align="center" valign="top">â†‘7%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â Rosuvastatin 10Â mg QD, <br>Â Â Â Â 14Â days</td>
<td class="Botrule" align="left" valign="top">10Â mg QD, 14Â days</td>
<td class="Botrule" align="center" valign="top">â†‘19%</td>
<td class="Botrule" align="center" valign="top">â†‘17%</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Â Â Â Â Fluvastatin 20Â mg QD, <br>Â Â Â Â 14Â days</td>
<td class="Botrule" align="left" valign="top">10Â mg QD, 14Â days</td>
<td class="Botrule" align="center" valign="top">â†“39%</td>
<td class="Botrule" align="center" valign="top">â†“27%</td>
</tr>
</tbody>
</table>
<p><span class="Italics">Simvastatin</span></p>
<a name="id_19c61f73-9421-44c0-977d-8061eb020d64"></a><table width="862.000">
<caption><span>Table 6: Effect of Coadministered Drugs or Grapefruit Juice on Simvastatin Systemic Exposure</span></caption>
<col width="16.4%">
<col width="19.4%">
<col width="17.2%">
<col width="17.2%">
<col width="13.3%">
<col width="16.6%">
<thead>
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="top"><span class="Bold">Coadministered Drug or Grapefruit Juice</span></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top"><span class="Bold">Dosing of Coadministered Drug or Grapefruit Juice</span></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top"><span class="Bold">Dosing of Simvastatin</span></td>
<td class="Botrule" align="center" colspan="3" valign="top">
<p class="First"><span class="Bold">Geometric Mean Ratio</span></p>
<p><span class="Bold">(Ratio<a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a></span><span class="Bold"> with / without <br>coadministered drug)</span></p>
<span class="Bold">No EffectÂ =Â 1.00</span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">AUC</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">C<span class="Sub">max</span></span></td>
</tr>
</thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>Results based on a chemical assay except results with propranolol as indicated.</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">â€ </a></dt>
<dd>Results could be representative of the following CYP3A4 inhibitors: ketoconazole, erythromycin, clarithromycin, HIV protease inhibitors, and nefazodone.</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">â€¡</a></dt>
<dd>Simvastatin acid refers to the Î²-hydroxyacid of simvastatin.</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">Â§</a></dt>
<dd>The effect of amounts of grapefruit juice between those used in these two studies on simvastatin pharmacokinetics has not been studied.</dd>
<dt><a name="footnote-18" href="#footnote-reference-18">Â¶</a></dt>
<dd>Double-strength: one can of frozen concentrate diluted with one can of water. Grapefruit juice was administered TID for 2Â days, and 200Â mL together with single dose simvastatin and 30 and 90Â minutes following single dose simvastatin on DayÂ 3.</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">#</a></dt>
<dd>Single-strength: one can of frozen concentrate diluted with 3Â cans of water. Grapefruit juice was administered with breakfast for 3Â days, and simvastatin was administered in the evening on DayÂ 3.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule" align="left" colspan="6" valign="top">
<span class="Bold">Avoid taking with VYTORIN </span><span class="Italics">[see <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a>]</span>
</td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Telithromycin<a name="footnote-reference-15" href="#footnote-15" class="Sup">â€ </a>
</td>
<td class="Botrule Rrule" align="center" valign="top">200Â mg QD for 4Â days</td>
<td class="Botrule Rrule" align="center" valign="top">80Â mg</td>
<td class="Botrule Rrule" align="left" valign="top">Â Â simvastatin acid<a name="footnote-reference-16" href="#footnote-16" class="Sup">â€¡</a><br>Â Â simvastatin </td>
<td class="Botrule Rrule" align="center" valign="top">12<br>8.9</td>
<td class="Botrule" align="center" valign="top">15<br>5.3</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Nelfinavir<a href="#footnote-15" class="Sup">â€ </a>
</td>
<td class="Botrule Rrule" align="center" valign="top">1250Â mg BID for 14Â days</td>
<td class="Botrule Rrule" align="center" valign="top">20Â mg QD for 28Â days</td>
<td class="Botrule Rrule" align="left" valign="top">Â Â simvastatin acid<a href="#footnote-16" class="Sup">â€¡</a><br>Â Â simvastatin </td>
<td class="Botrule Rrule" align="center" valign="top">
<br>6</td>
<td class="Botrule" align="center" valign="top">
<br>6.2</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Itraconazole<a href="#footnote-15" class="Sup">â€ </a>
</td>
<td class="Botrule Rrule" align="center" valign="top">200Â mg QD for 4Â days</td>
<td class="Botrule Rrule" align="center" valign="top">80Â mg</td>
<td class="Botrule Rrule" align="left" valign="top">Â Â simvastatin acid<a href="#footnote-16" class="Sup">â€¡</a><br>Â Â simvastatin </td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top">
<p class="First">13.1</p>13.1</td>
</tr>
<tr><td class="Botrule" align="left" colspan="6" valign="top">
<span class="Bold">Avoid &gt;1Â quart of grapefruit juice with VYTORIN </span><span class="Italics">[see <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a>]</span>
</td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Â Â Â Grapefruit Juice<a name="footnote-reference-17" href="#footnote-17" class="Sup">Â§</a></p>Â Â Â (high dose)</td>
<td class="Botrule Rrule" align="center" valign="top">200Â mL of double-strength TID<a name="footnote-reference-18" href="#footnote-18" class="Sup">Â¶</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">60Â mg single dose</td>
<td class="Botrule Rrule" align="left" valign="top">Â Â simvastatin acid<br>Â Â simvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">7<br>16</td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Â Â Â Grapefruit Juice<a href="#footnote-17" class="Sup">Â§</a></p>Â Â Â (low dose)</td>
<td class="Botrule Rrule" align="center" valign="top">8Â oz (about 237Â mL) of single-strength<a name="footnote-reference-19" href="#footnote-19" class="Sup">#</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">20Â mg single dose</td>
<td class="Botrule Rrule" align="left" valign="top">Â Â simvastatin acid<br>Â Â simvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">1.3<br>1.9</td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr><td class="Botrule" align="left" colspan="6" valign="top">
<span class="Bold">Avoid taking with VYTORIN. If VYTORIN is used in combination with gemfibrozil, the dose should not exceed 10/10Â mg daily</span>, based on clinical and/or post-marketing simvastatin experience <span class="Italics">[see <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a>]</span>
</td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Gemfibrozil</td>
<td class="Botrule Rrule" align="center" valign="top">600Â mg BID for 3Â days</td>
<td class="Botrule Rrule" align="center" valign="top">40Â mg</td>
<td class="Botrule Rrule" align="left" valign="top">Â Â simvastatin acid<br>Â Â simvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">2.85<br>1.35</td>
<td class="Botrule" align="center" valign="top">2.18<br>0.91</td>
</tr>
<tr><td class="Botrule" align="left" colspan="6" valign="top">
<span class="Bold">Avoid taking with &gt;10/20Â mg VYTORIN</span>, based on clinical and/or post-marketing simvastatin experience <span class="Italics">[see <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a>]</span>
</td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Verapamil SR</td>
<td class="Botrule Rrule" align="center" valign="top">240Â mg QD DaysÂ 1-7 then 240Â mg BID on DaysÂ 8-10</td>
<td class="Botrule Rrule" align="center" valign="top">80Â mg on Day 10</td>
<td class="Botrule Rrule" align="left" valign="top">Â Â simvastatin acid<br>Â Â simvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">2.3<br>2.5</td>
<td class="Botrule" align="center" valign="top">2.4<br>2.1</td>
</tr>
<tr><td class="Botrule" align="left" colspan="6" valign="top">
<span class="Bold">Avoid taking with &gt;10/40Â mg VYTORIN</span>, based on clinical and/or post-marketing simvastatin experience <span class="Italics">[see <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a>]</span>
</td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Diltiazem</td>
<td class="Botrule Rrule" align="center" valign="top">120Â mg BID for 10Â days</td>
<td class="Botrule Rrule" align="center" valign="top">80Â mg on DayÂ 10</td>
<td class="Botrule Rrule" align="left" valign="top">Â Â simvastatin acid<br>Â Â simvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">2.69<br>3.10</td>
<td class="Botrule" align="center" valign="top">2.69<br>2.88</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Diltiazem</td>
<td class="Botrule Rrule" align="center" valign="top">120Â mg BID for 14Â days</td>
<td class="Botrule Rrule" align="center" valign="top">20Â mg on Day 14</td>
<td class="Botrule Rrule" align="left" valign="top">Â Â simvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">4.6</td>
<td class="Botrule" align="center" valign="top">3.6</td>
</tr>
<tr><td class="Botrule" align="left" colspan="6" valign="top"><span class="Bold">No dosing adjustments required for the following:</span></td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Fenofibrate</td>
<td class="Botrule Rrule" align="center" valign="top">160Â mg QD x14Â days</td>
<td class="Botrule Rrule" align="center" valign="top">80 mg QD on DaysÂ 8-14</td>
<td class="Botrule Rrule" align="left" valign="top">Â Â simvastatin acid<br>Â Â simvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">0.64<br>0.89</td>
<td class="Botrule" align="center" valign="top">0.89<br>0.83</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Amlodipine</td>
<td class="Botrule Rrule" align="center" valign="top">10Â mg QD x 10Â days</td>
<td class="Botrule Rrule" align="center" valign="top">80Â mg on DayÂ 10</td>
<td class="Botrule Rrule" align="left" valign="top">Â Â simvastatin acid<br>Â Â simvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">1.58<br>1.77</td>
<td class="Botrule" align="center" valign="top">1.56<br>1.47</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Propranolol</td>
<td class="Rrule" align="center" valign="top">80Â mg single dose</td>
<td class="Rrule" align="center" valign="top">80Â mg single dose</td>
<td class="Rrule" align="left" valign="top">Â Â total inhibitor<br><br>Â Â active inhibitor</td>
<td class="Rrule" align="center" valign="top">0.79<br><br>0.79</td>
<td class="Botrule" align="center" valign="top">â†“ from 33.6 to 21.1 ngÂ·eq/ml<br>â†“ from 7.0 to 4.7 ngÂ·eq/mL</td>
</tr>
</tbody>
</table>
<p>Â </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_8b85e137-b318-4fac-8e5f-f13237689579"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_13ec6810-491a-4310-bf79-18bc3c433237"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Italics">VYTORIN</span></p>
<p>No animal carcinogenicity or fertility studies have been conducted with the combination of ezetimibe and simvastatin. The combination of ezetimibe with simvastatin did not show evidence of mutagenicity <span class="Italics">in vitro</span> in a microbial mutagenicity (Ames) test with <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium </span>and <span class="Italics">Escherichia coli </span>with or without metabolic activation. No evidence of clastogenicity was observed <span class="Italics">in vitro</span> in a chromosomal aberration assay in human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> with ezetimibe and simvastatin with or without metabolic activation. There was no evidence of genotoxicity at doses up to 600Â mg/kg with the combination of ezetimibe and simvastatin (1:1) in the <span class="Italics">in vivo</span> mouse micronucleus test.</p>
<p><span class="Italics">Ezetimibe</span></p>
<p>A 104-week dietary carcinogenicity study with ezetimibe was conducted in rats at doses up to 1500Â mg/kg/day (males) and 500Â mg/kg/day (females) (~20 times the human exposure at 10Â mg daily based on AUC<span class="Sub">0-24hr</span> for total ezetimibe). A 104-week dietary carcinogenicity study with ezetimibe was also conducted in mice at doses up to 500Â mg/kg/day (&gt;150 times the human exposure at 10Â mg daily based on AUC<span class="Sub">0-24hr </span>for total ezetimibe). There were no statistically significant increases in tumor incidences in drug-treated rats or mice. </p>
<p>No evidence of mutagenicity was observed <span class="Italics">in vitro</span> in a microbial mutagenicity (Ames) test with <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> and <span class="Italics">Escherichia coli</span> with or without metabolic activation. No evidence of clastogenicity was observed <span class="Italics">in vitro</span> in a chromosomal aberration assay in human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> with or without metabolic activation. In addition, there was no evidence of genotoxicity in the <span class="Italics">in vivo</span> mouse micronucleus test.</p>
<p>In oral (gavage) fertility studies of ezetimibe conducted in rats, there was no evidence of reproductive toxicity at doses up to 1000Â mg/kg/day in male or female rats (~7Â times the human exposure at 10Â mg daily based on AUC<span class="Sub">0-24hr</span> for total ezetimibe).</p>
<p><br><span class="Italics">Simvastatin</span></p>
<p>In a 72-week carcinogenicity study, mice were administered daily doses of simvastatin of 25, 100, and 400Â mg/kg body weight, which resulted in mean plasma drug levels approximately 1, 4, and 8Â times higher than the mean human plasma drug level, respectively, (as total inhibitory activity based on AUC) after an 80-mg oral dose. <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">Liver carcinomas</span> were significantly increased in high-dose females and mid- and high-dose males with a maximum incidence of 90% in males. The incidence of <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> of the liver was significantly increased in mid- and high-dose females. Drug treatment also significantly increased the incidence of lung <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in mid- and high-dose males and females. <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">Adenomas</span> of the Harderian gland (a gland of the eye of rodents) were significantly higher in high-dose mice than in controls. No evidence of a tumorigenic effect was observed at 25Â mg/kg/day. </p>
<p>In a separate 92-week carcinogenicity study in mice at doses up to 25Â mg/kg/day, no evidence of a tumorigenic effect was observed (mean plasma drug levels were 1Â times higher than humans given 80Â mg simvastatin as measured by AUC).</p>
<p>In a two-year study in rats at 25Â mg/kg/day, there was a statistically significant increase in the incidence of thyroid follicular <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in female rats exposed to approximately 11Â times higher levels of simvastatin than in humans given 80Â mg simvastatin (as measured by AUC).</p>
<p>A second two-year rat carcinogenicity study with doses of 50 and 100Â mg/kg/day produced <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> and carcinomas (in female rats at both doses and in males at 100Â mg/kg/day). Thyroid follicular cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> were increased in males and females at both doses; thyroid follicular cell carcinomas were increased in females at 100Â mg/kg/day. The increased incidence of thyroid neoplasms appears to be consistent with findings from other statins. These treatment levels represented plasma drug levels (AUC) of approximately 7 and 15Â times (males) and 22 and 25Â times (females) the mean human plasma drug exposure after an 80-mg daily dose.</p>
<p>No evidence of mutagenicity was observed in a microbial mutagenicity (Ames) test with or without rat or mouse liver metabolic activation. In addition, no evidence of damage to genetic material was noted in an <span class="Italics">in vitro</span> alkaline elution assay using rat hepatocytes, a V-79 mammalian cell forward mutation study, an <span class="Italics">in vitro</span> chromosome aberration study in CHO cells, or an <span class="Italics">in vivo</span> chromosomal aberration assay in mouse bone marrow.</p>
<p>There was decreased fertility in male rats treated with simvastatin for 34Â weeks at 25Â mg/kg body weight (4Â times the maximum human exposure level, based on AUC, in patients receiving 80Â mg/day); however, this effect was not observed during a subsequent fertility study in which simvastatin was administered at this same dose level to male rats for 11Â weeks (the entire cycle of spermatogenesis including epididymal maturation). No microscopic changes were observed in the testes of rats from either study. At 180Â mg/kg/day, (which produces exposure levels 22Â times higher than those in humans taking 80Â mg/day based on surface area, mg/m<span class="Sup">2</span>), seminiferous tubule degeneration (<span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> and loss of spermatogenic epithelium) was observed. In dogs, there was drug-related <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span>, decreased spermatogenesis, spermatocytic degeneration and giant cell formation at 10Â mg/kg/day (approximately 2Â times the human exposure, based on AUC, at 80Â mg/day). The clinical significance of these findings is unclear.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_5ebf0241-a904-4107-a612-a030e0975e46"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First"><span class="Italics"><span class="Bold">CNS Toxicity</span></span></p>
<p>Optic nerve degeneration was seen in clinically normal dogs treated with simvastatin for 14Â weeks at 180Â mg/kg/day, a dose that produced mean plasma drug levels about 12Â times higher than the mean plasma drug level in humans taking 80Â mg/day.</p>
<p>A chemically similar drug in this class also produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion starting at 60Â mg/kg/day, a dose that produced mean plasma drug levels about 30 times higher than the mean plasma drug level in humans taking the highest recommended dose (as measured by total enzyme inhibitory activity). This same drug also produced vestibulocochlear Wallerian-like degeneration and retinal <span class="product-label-link" type="condition" conceptid="72712" conceptname="Synovial cyst">ganglion</span> cell chromatolysis in dogs treated for 14Â weeks at 180Â mg/kg/day, a dose that resulted in a mean plasma drug level similar to that seen with the 60Â mg/kg/day dose.</p>
<p>CNS vascular lesions, characterized by perivascular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, mononuclear cell infiltration of perivascular spaces, perivascular fibrin deposits and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> of small vessels were seen in dogs treated with simvastatin at a dose of 360Â mg/kg/day, a dose that produced mean plasma drug levels that were about 14Â times higher than the mean plasma drug levels in humans taking 80Â mg/day. Similar CNS vascular lesions have been observed with several other drugs of this class.</p>
<p>There were <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span> in female rats after two years of treatment with 50 and 100Â mg/kg/day (22 and 25Â times the human AUC at 80Â mg/day, respectively) and in dogs after three months at 90Â mg/kg/day (19Â times) and at two years at 50Â mg/kg/day (5Â times).</p>
<p><br><span class="Italics">Ezetimibe</span></p>
<p>The hypocholesterolemic effect of ezetimibe was evaluated in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-fed Rhesus monkeys, dogs, rats, and mouse models of human <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> metabolism. Ezetimibe was found to have an ED<span class="Sub">50</span> value of 0.5Â Î¼g/kg/day for inhibiting the rise in plasma <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels in monkeys. The ED<span class="Sub">50</span> values in dogs, rats, and mice were 7, 30, and 700Â Î¼g/kg/day, respectively. These results are consistent with ezetimibe being a potent <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> absorption inhibitor.</p>
<p>In a rat model, where the glucuronide metabolite of ezetimibe (ezetimibe-glucuronide) was administered intraduodenally, the metabolite was as potent as ezetimibe in inhibiting the absorption of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, suggesting that the glucuronide metabolite had activity similar to the parent drug.</p>
<p>In 1-month studies in dogs given ezetimibe (0.03 to 300Â mg/kg/day), the concentration of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in gallbladder bile increased ~2- to 4-fold. However, a dose of 300Â mg/kg/day administered to dogs for one year did not result in gallstone formation or any other adverse hepatobiliary effects. In a 14-day study in mice given ezetimibe (0.3 to 5Â mg/kg/day) and fed a low-fat or <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-rich diet, the concentration of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in gallbladder bile was either unaffected or reduced to normal levels, respectively.</p>
<p>A series of acute preclinical studies was performed to determine the selectivity of ezetimibe for inhibiting <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> absorption. Ezetimibe inhibited the absorption of <span class="Sup">14</span>C-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> with no effect on the absorption of triglycerides, fatty acids, bile acids, progesterone, ethinyl estradiol, or the fat-soluble vitamins A and D.</p>
<p>In 4- to 12-week toxicity studies in mice, ezetimibe did not induce cytochrome P450 drug-metabolizing enzymes. In toxicity studies, a <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> of ezetimibe with statins (parents or their active hydroxy acid metabolites) was seen in rats, dogs, and rabbits.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_1f4b76ad-013f-408f-b639-d9a1b5e9ab6f"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c110b247-8838-4b65-872e-1ca062ff1cf2"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></h2>
<p class="First"><span class="Italics">VYTORIN</span></p>
<p>VYTORIN reduces total-C, LDL-C, ApoÂ B, TG, and non-HDL-C, and increases HDL-C in patients with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>. Maximal to near maximal response is generally achieved within 2Â weeks and maintained during chronic therapy.</p>
<p>VYTORIN is effective in men and women with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>. Experience in non-Caucasians is limited and does not permit a precise estimate of the magnitude of the effects of VYTORIN.</p>
<p>Five multicenter, double-blind studies conducted with either VYTORIN or coadministered ezetimibe and simvastatin equivalent to VYTORIN in patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> are reported: two were comparisons with simvastatin, two were comparisons with atorvastatin, and one was a comparison with rosuvastatin.</p>
<p>In a multicenter, double-blind, placebo-controlled, 12-week trial, 1528Â hyperlipidemic patients were randomized to one of ten treatment groups: placebo, ezetimibe (10Â mg), simvastatin (10Â mg, 20Â mg, 40Â mg, or 80Â mg), or VYTORIN (10/10, 10/20, 10/40, or 10/80).</p>
<p>When patients receiving VYTORIN were compared to those receiving all doses of simvastatin, VYTORIN significantly lowered total-C, LDL-C, ApoÂ B, TG, and non-HDL-C. The effects of VYTORIN on HDL-C were similar to the effects seen with simvastatin. Further analysis showed VYTORIN significantly increased HDL-C compared with placebo. (See TableÂ 7.) The lipid response to VYTORIN was similar in patients with TG levels greater than or less than 200Â mg/dL.</p>
<a name="id_1f51b28f-0c87-4c40-8be9-fb471b87a61e"></a><table width="701.000">
<caption><span>Table 7: Response to VYTORIN in Patients with Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Mean<a name="footnote-reference-20" href="#footnote-20" class="Sup">*</a>Â % Change from Untreated Baseline<a name="footnote-reference-21" href="#footnote-21" class="Sup">â€ </a>)</span></caption>
<col width="29.2%">
<col width="9.7%">
<col width="9.7%">
<col width="9.7%">
<col width="9.7%">
<col width="9.7%">
<col width="10.7%">
<col width="11.6%">
<thead><tr class="First Last">
<td class="Botrule" align="center" valign="bottom">Treatment<br>(Daily Dose)</td>
<td class="Botrule" align="center" valign="bottom">N</td>
<td class="Botrule" align="center" valign="bottom">Total-C</td>
<td class="Botrule" align="center" valign="bottom">LDL-C</td>
<td class="Botrule" align="center" valign="bottom"><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span></td>
<td class="Botrule" align="center" valign="bottom">HDL-C</td>
<td class="Botrule" align="center" valign="bottom">TG<a href="#footnote-20" class="Sup">*</a>
</td>
<td class="Botrule" align="center" valign="bottom">Non-HDL-C</td>
</tr></thead>
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-20" href="#footnote-reference-20">*</a></dt>
<dd>For triglycerides, median % change from baseline</dd>
<dt><a name="footnote-21" href="#footnote-reference-21">â€ </a></dt>
<dd>Baseline - on no lipid-lowering drug</dd>
<dt><a name="footnote-22" href="#footnote-reference-22">â€¡</a></dt>
<dd>VYTORIN doses pooled (10/10-10/80) significantly reduced total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, TG, and non-HDL-C compared to simvastatin and significantly increased HDL-C compared to placebo.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="middle">Pooled data (All VYTORIN doses)<a name="footnote-reference-22" href="#footnote-22" class="Sup">â€¡</a>
</td>
<td class="Botrule" align="center" valign="middle">609</td>
<td class="Botrule" align="center" valign="middle">-38</td>
<td class="Botrule" align="center" valign="middle">-53</td>
<td class="Botrule" align="center" valign="middle">-42</td>
<td class="Botrule" align="center" valign="middle">+7</td>
<td class="Botrule" align="center" valign="middle">-24</td>
<td class="Botrule" align="center" valign="middle">-49</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Pooled data (All simvastatin doses)<a href="#footnote-22" class="Sup">â€¡</a>
</td>
<td class="Botrule" align="center" valign="middle">622</td>
<td class="Botrule" align="center" valign="middle">-28</td>
<td class="Botrule" align="center" valign="middle">-39</td>
<td class="Botrule" align="center" valign="middle">-32</td>
<td class="Botrule" align="center" valign="middle">+7</td>
<td class="Botrule" align="center" valign="middle">-21</td>
<td class="Botrule" align="center" valign="middle">-36</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Ezetimibe 10 mg</td>
<td class="Botrule" align="center" valign="middle">149</td>
<td class="Botrule" align="center" valign="middle">-13</td>
<td class="Botrule" align="center" valign="middle">-19</td>
<td class="Botrule" align="center" valign="middle">-15</td>
<td class="Botrule" align="center" valign="middle">+5</td>
<td class="Botrule" align="center" valign="middle">-11</td>
<td class="Botrule" align="center" valign="middle">-18</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Placebo</td>
<td class="Botrule" align="center" valign="middle">148</td>
<td class="Botrule" align="center" valign="middle">-1</td>
<td class="Botrule" align="center" valign="middle">-2</td>
<td class="Botrule" align="center" valign="middle">0</td>
<td class="Botrule" align="center" valign="middle">0</td>
<td class="Botrule" align="center" valign="middle">-2</td>
<td class="Botrule" align="center" valign="middle">-2</td>
</tr>
<tr>
<td align="left" valign="middle">VYTORIN by dose</td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10/10</td>
<td class="Botrule" align="center" valign="middle">152</td>
<td class="Botrule" align="center" valign="middle">-31</td>
<td class="Botrule" align="center" valign="middle">-45</td>
<td class="Botrule" align="center" valign="middle">-35</td>
<td class="Botrule" align="center" valign="middle">+8</td>
<td class="Botrule" align="center" valign="middle">-23</td>
<td class="Botrule" align="center" valign="middle">-41</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10/20</td>
<td class="Botrule" align="center" valign="middle">156</td>
<td class="Botrule" align="center" valign="middle">-36</td>
<td class="Botrule" align="center" valign="middle">-52</td>
<td class="Botrule" align="center" valign="middle">-41</td>
<td class="Botrule" align="center" valign="middle">+10</td>
<td class="Botrule" align="center" valign="middle">-24</td>
<td class="Botrule" align="center" valign="middle">-47</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10/40</td>
<td class="Botrule" align="center" valign="middle">147</td>
<td class="Botrule" align="center" valign="middle">-39</td>
<td class="Botrule" align="center" valign="middle">-55</td>
<td class="Botrule" align="center" valign="middle">-44</td>
<td class="Botrule" align="center" valign="middle">+6</td>
<td class="Botrule" align="center" valign="middle">-23</td>
<td class="Botrule" align="center" valign="middle">-51</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10/80</td>
<td class="Botrule" align="center" valign="middle">154</td>
<td class="Botrule" align="center" valign="middle">-43</td>
<td class="Botrule" align="center" valign="middle">-60</td>
<td class="Botrule" align="center" valign="middle">-49</td>
<td class="Botrule" align="center" valign="middle">+6</td>
<td class="Botrule" align="center" valign="middle">-31</td>
<td class="Botrule" align="center" valign="middle">-56</td>
</tr>
<tr>
<td align="left" valign="middle">Simvastatin by dose</td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10 mg</td>
<td class="Botrule" align="center" valign="middle">158</td>
<td class="Botrule" align="center" valign="middle">-23</td>
<td class="Botrule" align="center" valign="middle">-33</td>
<td class="Botrule" align="center" valign="middle">-26</td>
<td class="Botrule" align="center" valign="middle">+5</td>
<td class="Botrule" align="center" valign="middle">-17</td>
<td class="Botrule" align="center" valign="middle">-30</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">20 mg</td>
<td class="Botrule" align="center" valign="middle">150</td>
<td class="Botrule" align="center" valign="middle">-24</td>
<td class="Botrule" align="center" valign="middle">-34</td>
<td class="Botrule" align="center" valign="middle">-28</td>
<td class="Botrule" align="center" valign="middle">+7</td>
<td class="Botrule" align="center" valign="middle">-18</td>
<td class="Botrule" align="center" valign="middle">-32</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">40 mg</td>
<td class="Botrule" align="center" valign="middle">156</td>
<td class="Botrule" align="center" valign="middle">-29</td>
<td class="Botrule" align="center" valign="middle">-41</td>
<td class="Botrule" align="center" valign="middle">-33</td>
<td class="Botrule" align="center" valign="middle">+8</td>
<td class="Botrule" align="center" valign="middle">-21</td>
<td class="Botrule" align="center" valign="middle">-38</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="middle">80 mg</td>
<td class="Botrule" align="center" valign="middle">158</td>
<td class="Botrule" align="center" valign="middle">-35</td>
<td class="Botrule" align="center" valign="middle">-49</td>
<td class="Botrule" align="center" valign="middle">-39</td>
<td class="Botrule" align="center" valign="middle">+7</td>
<td class="Botrule" align="center" valign="middle">-27</td>
<td class="Botrule" align="center" valign="middle">-45</td>
</tr>
</tbody>
</table>
<p>In a multicenter, double-blind, controlled, 23-week study, 710Â patients with known CHD or CHD risk equivalents, as defined by the NCEP ATP III guidelines, and an LDL-C â‰¥130Â mg/dL were randomized to one of four treatment groups: coadministered ezetimibe and simvastatin equivalent to VYTORIN (10/10, 10/20, and 10/40) or simvastatin 20Â mg. Patients not reaching an LDL-C &lt;100Â mg/dL had their simvastatin dose titrated at 6-week intervals to a maximal dose of 80Â mg.</p>
<p>At WeekÂ 5, the LDL-C reductions with VYTORIN 10/10, 10/20, or 10/40 were significantly larger than with simvastatin 20Â mg (see Table 8).</p>
<a name="id_26f70869-7bd7-4f00-bd9d-4dd6e9781fc5"></a><table width="482.000">
<caption><span>Table 8: Response to VYTORIN after 5 Weeks in Patients with CHD or CHD Risk Equivalents and an LDL-C â‰¥130Â mg/dL</span></caption>
<col width="28.4%">
<col width="19.3%">
<col width="17.0%">
<col width="18.3%">
<col width="17.0%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="center" valign="middle">Simvastatin<br>20Â mg</td>
<td class="Botrule" align="center" valign="middle">VYTORIN<br>10/10</td>
<td class="Botrule" align="center" valign="middle">VYTORIN<br>10/20</td>
<td class="Botrule" align="center" valign="middle">VYTORIN<br>10/40</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="middle">N</td>
<td class="Botrule" align="center" valign="middle">253</td>
<td class="Botrule" align="center" valign="middle">251</td>
<td class="Botrule" align="center" valign="middle">109</td>
<td class="Botrule" align="center" valign="middle">97</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Mean baseline<br>LDL-C</td>
<td class="Botrule" align="center" valign="middle">174</td>
<td class="Botrule" align="center" valign="middle">165</td>
<td class="Botrule" align="center" valign="middle">167</td>
<td class="Botrule" align="center" valign="middle">171</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="middle">Percent change<br>LDL-C</td>
<td class="Botrule" align="center" valign="middle">-38</td>
<td class="Botrule" align="center" valign="middle">-47</td>
<td class="Botrule" align="center" valign="middle">-53</td>
<td class="Botrule" align="center" valign="middle">-59</td>
</tr>
</tbody>
</table>
<p>In a multicenter, double-blind, 6-week study, 1902 patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, who had not met their NCEP ATP III target LDL-C goal, were randomized to one of eight treatment groups: VYTORIN (10/10, 10/20, 10/40, or 10/80) or atorvastatin (10 mg, 20 mg, 40 mg, or 80 mg).</p>
<p>Across the dosage range, when patients receiving VYTORIN were compared to those receiving milligram-equivalent statin doses of atorvastatin, VYTORIN lowered total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, and non-HDL-C significantly more than atorvastatin. Only the 10/40Â mg and 10/80Â mg VYTORIN doses increased HDL-C significantly more than the corresponding milligram-equivalent statin dose of atorvastatin. The effects of VYTORIN on TG were similar to the effects seen with atorvastatin. (See TableÂ 9.)</p>
<a name="id_12e0261d-7ab1-47b8-a7dd-7536affe5596"></a><table width="637.000">
<caption><span>Table 9: Response to VYTORIN and Atorvastatin in Patients with Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Mean<a name="footnote-reference-23" href="#footnote-23" class="Sup">*</a> % Change from Untreated Baseline<a name="footnote-reference-24" href="#footnote-24" class="Sup">â€ </a>) </span></caption>
<col width="22.4%">
<col width="10.4%">
<col width="11.1%">
<col width="10.4%">
<col width="10.4%">
<col width="10.4%">
<col width="11.1%">
<col width="13.8%">
<thead><tr class="First Last">
<td class="Botrule" align="center" valign="bottom">Treatment<br>(Daily Dose)</td>
<td class="Botrule" align="center" valign="bottom">N</td>
<td class="Botrule" align="center" valign="bottom">Total-C<a name="footnote-reference-25" href="#footnote-25" class="Sup">â€¡</a>
</td>
<td class="Botrule" align="center" valign="bottom">LDL-C<a href="#footnote-25" class="Sup">â€¡</a>
</td>
<td class="Botrule" align="center" valign="bottom"><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span><a href="#footnote-25" class="Sup">â€¡</a>
</td>
<td class="Botrule" align="center" valign="bottom">HDL-C</td>
<td class="Botrule" align="center" valign="bottom">TG<a href="#footnote-23" class="Sup">*</a>
</td>
<td class="Botrule" align="center" valign="bottom">Non-HDL-C<a href="#footnote-25" class="Sup">â€¡</a>
</td>
</tr></thead>
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-23" href="#footnote-reference-23">*</a></dt>
<dd>For triglycerides, median % change from baseline</dd>
<dt><a name="footnote-24" href="#footnote-reference-24">â€ </a></dt>
<dd>Baseline - on no lipid-lowering drug</dd>
<dt><a name="footnote-25" href="#footnote-reference-25">â€¡</a></dt>
<dd>VYTORIN doses pooled (10/10-10/80) provided significantly greater reductions in total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, and non-HDL-C compared to atorvastatin doses pooled (10-80).</dd>
<dt><a name="footnote-26" href="#footnote-reference-26">Â§</a></dt>
<dd>p&lt;0.05 for difference with atorvastatin at equal mg doses of the simvastatin component</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="middle">VYTORIN by dose</td>
<td class="Toprule" align="center" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10/10</td>
<td class="Botrule" align="center" valign="middle">230</td>
<td class="Botrule" align="center" valign="middle">-34<a name="footnote-reference-26" href="#footnote-26" class="Sup">Â§</a>
</td>
<td class="Botrule" align="center" valign="middle">-47<a href="#footnote-26" class="Sup">Â§</a>
</td>
<td class="Botrule" align="center" valign="middle">-37<a href="#footnote-26" class="Sup">Â§</a>
</td>
<td class="Botrule" align="center" valign="middle">+8</td>
<td class="Botrule" align="center" valign="middle">-26</td>
<td class="Botrule" align="center" valign="middle">-43<a href="#footnote-26" class="Sup">Â§</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10/20</td>
<td class="Botrule" align="center" valign="middle">233</td>
<td class="Botrule" align="center" valign="middle">-37<a href="#footnote-26" class="Sup">Â§</a>
</td>
<td class="Botrule" align="center" valign="middle">-51<a href="#footnote-26" class="Sup">Â§</a>
</td>
<td class="Botrule" align="center" valign="middle">-40<a href="#footnote-26" class="Sup">Â§</a>
</td>
<td class="Botrule" align="center" valign="middle">+7</td>
<td class="Botrule" align="center" valign="middle">-25</td>
<td class="Botrule" align="center" valign="middle">-46<a href="#footnote-26" class="Sup">Â§</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10/40</td>
<td class="Botrule" align="center" valign="middle">236</td>
<td class="Botrule" align="center" valign="middle">-41<a href="#footnote-26" class="Sup">Â§</a>
</td>
<td class="Botrule" align="center" valign="middle">-57<a href="#footnote-26" class="Sup">Â§</a>
</td>
<td class="Botrule" align="center" valign="middle">-46<a href="#footnote-26" class="Sup">Â§</a>
</td>
<td class="Botrule" align="center" valign="middle">+9<a href="#footnote-26" class="Sup">Â§</a>
</td>
<td class="Botrule" align="center" valign="middle">-27</td>
<td class="Botrule" align="center" valign="middle">-52<a href="#footnote-26" class="Sup">Â§</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10/80</td>
<td class="Botrule" align="center" valign="middle">224</td>
<td class="Botrule" align="center" valign="middle">-43<a href="#footnote-26" class="Sup">Â§</a>
</td>
<td class="Botrule" align="center" valign="middle">-59<a href="#footnote-26" class="Sup">Â§</a>
</td>
<td class="Botrule" align="center" valign="middle">-48<a href="#footnote-26" class="Sup">Â§</a>
</td>
<td class="Botrule" align="center" valign="middle">+8<a href="#footnote-26" class="Sup">Â§</a>
</td>
<td class="Botrule" align="center" valign="middle">-31</td>
<td class="Botrule" align="center" valign="middle">-54<a href="#footnote-26" class="Sup">Â§</a>
</td>
</tr>
<tr>
<td align="left" valign="middle">Atorvastatin by dose</td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10 mg</td>
<td class="Botrule" align="center" valign="middle">235</td>
<td class="Botrule" align="center" valign="middle">-27</td>
<td class="Botrule" align="center" valign="middle">-36</td>
<td class="Botrule" align="center" valign="middle">-31</td>
<td class="Botrule" align="center" valign="middle">+7</td>
<td class="Botrule" align="center" valign="middle">-21</td>
<td class="Botrule" align="center" valign="middle">-34</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">20 mg</td>
<td class="Botrule" align="center" valign="middle">230</td>
<td class="Botrule" align="center" valign="middle">-32</td>
<td class="Botrule" align="center" valign="middle">-44</td>
<td class="Botrule" align="center" valign="middle">-37</td>
<td class="Botrule" align="center" valign="middle">+5</td>
<td class="Botrule" align="center" valign="middle">-25</td>
<td class="Botrule" align="center" valign="middle">-41</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">40 mg</td>
<td class="Botrule" align="center" valign="middle">232</td>
<td class="Botrule" align="center" valign="middle">-36</td>
<td class="Botrule" align="center" valign="middle">-48</td>
<td class="Botrule" align="center" valign="middle">-40</td>
<td class="Botrule" align="center" valign="middle">+4</td>
<td class="Botrule" align="center" valign="middle">-24</td>
<td class="Botrule" align="center" valign="middle">-45</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="middle">80 mg</td>
<td class="Botrule" align="center" valign="middle">230</td>
<td class="Botrule" align="center" valign="middle">-40</td>
<td class="Botrule" align="center" valign="middle">-53</td>
<td class="Botrule" align="center" valign="middle">-44</td>
<td class="Botrule" align="center" valign="middle">+1</td>
<td class="Botrule" align="center" valign="middle">-32</td>
<td class="Botrule" align="center" valign="middle">-50</td>
</tr>
</tbody>
</table>
<p>In a multicenter, double-blind, 24-week, forced-titration study, 788Â patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, who had not met their NCEP ATP III target LDL-C goal, were randomized to receive coadministered ezetimibe and simvastatin equivalent to VYTORIN (10/10 and 10/20) or atorvastatin 10Â mg. For all three treatment groups, the dose of the statin was titrated at 6-week intervals to 80Â mg. At each pre-specified dose comparison, VYTORIN lowered LDL-C to a greater degree than atorvastatin (see TableÂ 10). </p>
<a name="id_b971b171-1f13-4430-b31a-5b52f793092a"></a><table width="752.000">
<caption><span>Table 10: Response to VYTORIN and Atorvastatin in Patients with Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Mean<a name="footnote-reference-27" href="#footnote-27" class="Sup">*</a>Â % Change from Untreated Baseline<a name="footnote-reference-28" href="#footnote-28" class="Sup">â€ </a>)</span></caption>
<col width="21.1%">
<col width="8.8%">
<col width="9.4%">
<col width="10.2%">
<col width="11.7%">
<col width="12.4%">
<col width="13.2%">
<col width="13.2%">
<thead><tr class="First Last">
<td class="Botrule" align="center" valign="bottom">Treatment</td>
<td class="Botrule" align="center" valign="bottom">N</td>
<td class="Botrule" align="center" valign="bottom">Total-C</td>
<td class="Botrule" align="center" valign="bottom">LDL-C</td>
<td class="Botrule" align="center" valign="bottom"><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span></td>
<td class="Botrule" align="center" valign="bottom">HDL-C</td>
<td class="Botrule" align="center" valign="bottom">TG<a href="#footnote-27" class="Sup">*</a>
</td>
<td class="Botrule" align="center" valign="bottom">Non-HDL-C</td>
</tr></thead>
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-27" href="#footnote-reference-27">*</a></dt>
<dd>For triglycerides, median % change from baseline</dd>
<dt><a name="footnote-28" href="#footnote-reference-28">â€ </a></dt>
<dd>Baseline - on no lipid-lowering drug</dd>
<dt><a name="footnote-29" href="#footnote-reference-29">â€¡</a></dt>
<dd>Atorvastatin: 10Â mg start dose titrated to 20Â mg, 40Â mg, and 80Â mg through Weeks 6, 12, 18, and 24</dd>
<dt><a name="footnote-30" href="#footnote-reference-30">Â§</a></dt>
<dd>VYTORIN: 10/10 start dose titrated to 10/20, 10/40, and 10/80 through Weeks 6, 12, 18, and 24</dd>
<dt><a name="footnote-31" href="#footnote-reference-31">Â¶</a></dt>
<dd>pâ‰¤0.05 for difference with atorvastatin in the specified week</dd>
<dt><a name="footnote-32" href="#footnote-reference-32">#</a></dt>
<dd>VYTORIN: 10/20 start dose titrated to 10/40, 10/40, and 10/80 through Weeks 6, 12, 18, and 24</dd>
<dt><a name="footnote-33" href="#footnote-reference-33">Ãž</a></dt>
<dd>Data pooled for common doses of VYTORIN at Weeks 18 and 24.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="middle">Week 6</td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Atorvastatin 10Â mg<a name="footnote-reference-29" href="#footnote-29" class="Sup">â€¡</a>
</td>
<td class="Botrule" align="center" valign="middle">262</td>
<td class="Botrule" align="center" valign="middle">-28</td>
<td class="Botrule" align="center" valign="middle">-37</td>
<td class="Botrule" align="center" valign="middle">-32</td>
<td class="Botrule" align="center" valign="middle">+5</td>
<td class="Botrule" align="center" valign="middle">-23</td>
<td class="Botrule" align="center" valign="middle">-35</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">VYTORIN10/10<a name="footnote-reference-30" href="#footnote-30" class="Sup">Â§</a>
</td>
<td class="Botrule" align="center" valign="middle">263</td>
<td class="Botrule" align="center" valign="middle">-34<a name="footnote-reference-31" href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">-46<a href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">-38<a href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">+8<a href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">-26</td>
<td class="Botrule" align="center" valign="middle">-43<a href="#footnote-31" class="Sup">Â¶</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">VYTORIN 10/20<a name="footnote-reference-32" href="#footnote-32" class="Sup">#</a>
</td>
<td class="Botrule" align="center" valign="middle">263</td>
<td class="Botrule" align="center" valign="middle">-36<a href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">-50<a href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">-41<a href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">+10<a href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">-25</td>
<td class="Botrule" align="center" valign="middle">-46<a href="#footnote-31" class="Sup">Â¶</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Week 12</td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Atorvastatin 20Â mg</td>
<td class="Botrule" align="center" valign="middle">246</td>
<td class="Botrule" align="center" valign="middle">-33</td>
<td class="Botrule" align="center" valign="middle">-44</td>
<td class="Botrule" align="center" valign="middle">-38</td>
<td class="Botrule" align="center" valign="middle">+7</td>
<td class="Botrule" align="center" valign="middle">-28</td>
<td class="Botrule" align="center" valign="middle">-42</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">VYTORIN 10/20</td>
<td class="Botrule" align="center" valign="middle">250</td>
<td class="Botrule" align="center" valign="middle">-37<a href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">-50<a href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">-41<a href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">+9</td>
<td class="Botrule" align="center" valign="middle">-28</td>
<td class="Botrule" align="center" valign="middle">-46<a href="#footnote-31" class="Sup">Â¶</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">VYTORIN 10/40</td>
<td class="Botrule" align="center" valign="middle">252</td>
<td class="Botrule" align="center" valign="middle">-39<a href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">-54<a href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">-45<a href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">+12<a href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">-31</td>
<td class="Botrule" align="center" valign="middle">-50<a href="#footnote-31" class="Sup">Â¶</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Week 18</td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Atorvastatin 40Â mg</td>
<td class="Botrule" align="center" valign="middle">237</td>
<td class="Botrule" align="center" valign="middle">-37</td>
<td class="Botrule" align="center" valign="middle">-49</td>
<td class="Botrule" align="center" valign="middle">-42</td>
<td class="Botrule" align="center" valign="middle">+8</td>
<td class="Botrule" align="center" valign="middle">-31</td>
<td class="Botrule" align="center" valign="middle">-47</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">VYTORIN 10/40<a name="footnote-reference-33" href="#footnote-33" class="Sup">Ãž</a>
</td>
<td class="Botrule" align="center" valign="middle">482</td>
<td class="Botrule" align="center" valign="middle">-40<a href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">-56<a href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">-45<a href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">+11<a href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">-32</td>
<td class="Botrule" align="center" valign="middle">-52<a href="#footnote-31" class="Sup">Â¶</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Week 24</td>
<td class="Botrule" align="center" valign="middle"></td>
<td class="Botrule" align="center" valign="middle"></td>
<td class="Botrule" align="center" valign="middle"></td>
<td class="Botrule" align="center" valign="middle"></td>
<td class="Botrule" align="center" valign="middle"></td>
<td class="Botrule" align="center" valign="middle"></td>
<td class="Botrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Atorvastatin 80Â mg</td>
<td class="Botrule" align="center" valign="middle">228</td>
<td class="Botrule" align="center" valign="middle">-40</td>
<td class="Botrule" align="center" valign="middle">-53</td>
<td class="Botrule" align="center" valign="middle">-45</td>
<td class="Botrule" align="center" valign="middle">+6</td>
<td class="Botrule" align="center" valign="middle">-35</td>
<td class="Botrule" align="center" valign="middle">-50</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="middle">VYTORIN 10/80<a href="#footnote-33" class="Sup">Ãž</a>
</td>
<td class="Botrule" align="center" valign="middle">459</td>
<td class="Botrule" align="center" valign="middle">-43<a href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">-59<a href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">-49<a href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">+12<a href="#footnote-31" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">-35</td>
<td class="Botrule" align="center" valign="middle">-55<a href="#footnote-31" class="Sup">Â¶</a>
</td>
</tr>
</tbody>
</table>
<p>In a multicenter, double-blind, 6-week study, 2959 patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, who had not met their NCEP ATP III target LDL-C goal, were randomized to one of six treatment groups: VYTORIN (10/20, 10/40, or 10/80) or rosuvastatin (10 mg, 20 mg, or 40 mg).</p>
<p>The effects of VYTORIN and rosuvastatin on total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, TG, non-HDL-C and HDL-C are shown in TableÂ 11.</p>
<a name="id_492a5480-883e-432c-8815-bc32c6f8bf59"></a><table width="642.000">
<caption><span>Table 11: Response to VYTORIN and Rosuvastatin in Patients with Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Mean<a name="footnote-reference-34" href="#footnote-34" class="Sup">*</a>Â % Change from Untreated Baseline<a name="footnote-reference-35" href="#footnote-35" class="Sup">â€ </a>)</span></caption>
<col width="22.3%">
<col width="12.0%">
<col width="11.1%">
<col width="10.3%">
<col width="11.1%">
<col width="10.3%">
<col width="11.1%">
<col width="12.0%">
<thead><tr class="First Last">
<td class="Botrule" align="center" valign="bottom">Treatment<br>(Daily Dose)</td>
<td class="Botrule" align="center" valign="bottom">N</td>
<td class="Botrule" align="center" valign="bottom">Total-C<a name="footnote-reference-36" href="#footnote-36" class="Sup">â€¡</a>
</td>
<td class="Botrule" align="center" valign="bottom">LDL-C<a href="#footnote-36" class="Sup">â€¡</a>
</td>
<td class="Botrule" align="center" valign="bottom"><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span><a href="#footnote-36" class="Sup">â€¡</a>
</td>
<td class="Botrule" align="center" valign="bottom">HDL-C</td>
<td class="Botrule" align="center" valign="bottom">TG<a href="#footnote-34" class="Sup">*</a>
</td>
<td class="Botrule" align="center" valign="bottom">Non-HDL-C<a href="#footnote-36" class="Sup">â€¡</a>
</td>
</tr></thead>
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-34" href="#footnote-reference-34">*</a></dt>
<dd>For triglycerides, median % change from baseline</dd>
<dt><a name="footnote-35" href="#footnote-reference-35">â€ </a></dt>
<dd>Baseline - on no lipid-lowering drug</dd>
<dt><a name="footnote-36" href="#footnote-reference-36">â€¡</a></dt>
<dd>VYTORIN doses pooled (10/20-10/80) provided significantly greater reductions in total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, and non-HDL-C compared to rosuvastatin doses pooled (10-40Â mg).</dd>
<dt><a name="footnote-37" href="#footnote-reference-37">Â§</a></dt>
<dd>p&lt;0.05 vs. rosuvastatin 10Â mg</dd>
<dt><a name="footnote-38" href="#footnote-reference-38">Â¶</a></dt>
<dd>p&lt;0.05 vs. rosuvastatin 20Â mg</dd>
<dt><a name="footnote-39" href="#footnote-reference-39">#</a></dt>
<dd> p&lt;0.05 vs. rosuvastatin 40Â mg</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">VYTORIN by dose<br>10/20</td>
<td class="Botrule" align="center" valign="bottom">476</td>
<td class="Botrule" align="center" valign="bottom">-37<a name="footnote-reference-37" href="#footnote-37" class="Sup">Â§</a>
</td>
<td class="Botrule" align="center" valign="bottom">-52<a href="#footnote-37" class="Sup">Â§</a>
</td>
<td class="Botrule" align="center" valign="bottom">-42<a href="#footnote-37" class="Sup">Â§</a>
</td>
<td class="Botrule" align="center" valign="bottom">+7</td>
<td class="Botrule" align="center" valign="bottom">-23<a href="#footnote-37" class="Sup">Â§</a>
</td>
<td class="Botrule" align="center" valign="bottom">-47<a href="#footnote-37" class="Sup">Â§</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10/40</td>
<td class="Botrule" align="center" valign="middle">477</td>
<td class="Botrule" align="center" valign="middle">-39<a name="footnote-reference-38" href="#footnote-38" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">-55<a href="#footnote-38" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">-44<a href="#footnote-38" class="Sup">Â¶</a>
</td>
<td class="Botrule" align="center" valign="middle">+8</td>
<td class="Botrule" align="center" valign="middle">-27</td>
<td class="Botrule" align="center" valign="middle">-50<a href="#footnote-38" class="Sup">Â¶</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10/80</td>
<td class="Botrule" align="center" valign="middle">474</td>
<td class="Botrule" align="center" valign="middle">-44<a name="footnote-reference-39" href="#footnote-39" class="Sup">#</a>
</td>
<td class="Botrule" align="center" valign="middle">-61<a href="#footnote-39" class="Sup">#</a>
</td>
<td class="Botrule" align="center" valign="middle">-50<a href="#footnote-39" class="Sup">#</a>
</td>
<td class="Botrule" align="center" valign="middle">+8</td>
<td class="Botrule" align="center" valign="middle">-30<a href="#footnote-39" class="Sup">#</a>
</td>
<td class="Botrule" align="center" valign="middle">-56<a href="#footnote-39" class="Sup">#</a>
</td>
</tr>
<tr>
<td align="left" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Rosuvastatin by dose<br>10 mg</td>
<td class="Botrule" align="center" valign="bottom">475</td>
<td class="Botrule" align="center" valign="bottom">-32</td>
<td class="Botrule" align="center" valign="bottom">-46</td>
<td class="Botrule" align="center" valign="bottom">-37</td>
<td class="Botrule" align="center" valign="bottom">+7</td>
<td class="Botrule" align="center" valign="bottom">-20</td>
<td class="Botrule" align="center" valign="bottom">-42</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">20 mg</td>
<td class="Botrule" align="center" valign="middle">478</td>
<td class="Botrule" align="center" valign="middle">-37</td>
<td class="Botrule" align="center" valign="middle">-52</td>
<td class="Botrule" align="center" valign="middle">-43</td>
<td class="Botrule" align="center" valign="middle">+8</td>
<td class="Botrule" align="center" valign="middle">-26</td>
<td class="Botrule" align="center" valign="middle">-48</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="middle">40 mg</td>
<td class="Botrule" align="center" valign="middle">475</td>
<td class="Botrule" align="center" valign="middle">-41</td>
<td class="Botrule" align="center" valign="middle">-57</td>
<td class="Botrule" align="center" valign="middle">-47</td>
<td class="Botrule" align="center" valign="middle">+8</td>
<td class="Botrule" align="center" valign="middle">-28</td>
<td class="Botrule" align="center" valign="middle">-52</td>
</tr>
</tbody>
</table>
<p>In a multicenter, double-blind, 24-week trial, 214Â patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus treated with thiazolidinediones (rosiglitazone or pioglitazone) for a minimum of 3Â months and simvastatin 20Â mg for a minimum of 6Â weeks were randomized to receive either simvastatin 40Â mg or the coadministered active ingredients equivalent to VYTORIN 10/20. The median LDL-C and HbA1c levels at baseline were 89Â mg/dL and 7.1%, respectively.</p>
<p>VYTORIN 10/20 was significantly more effective than doubling the dose of simvastatin to 40Â mg. The median percent changes from baseline for VYTORIN vs. simvastatin were: LDL-C -25% and -5%; total-C -16% and -5%; ApoÂ B -19% and -5%; and non-HDL-C -23% and -5%. Results for HDL-C and TG between the two treatment groups were not significantly different.</p>
<p><br><span class="Italics">Ezetimibe</span></p>
<p>In two multicenter, double-blind, placebo-controlled, 12-week studies in 1719Â patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, ezetimibe significantly lowered total-C (-13%), LDL-C (-19%), ApoÂ B (-14%), and TGÂ (-8%), and increased HDL-C (+3%) compared to placebo. Reduction in LDL-C was consistent across age, sex, and baseline LDL-C.</p>
<p><br><span class="Italics">Simvastatin</span></p>
<p>In two large, placebo-controlled clinical trials, the Scandinavian Simvastatin Survival Study (N=4,444 patients) and the Heart Protection Study (N=20,536 patients), the effects of treatment with simvastatin were assessed in patients at high risk of coronary events because of existing coronary heart disease, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, peripheral vessel disease, history of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or other cerebrovascular disease. Simvastatin was proven to reduce: the risk of total mortality by reducing CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>; the risk of non-fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>; and the need for coronary and non-coronary revascularization procedures. </p>
<p>No incremental benefit of VYTORIN on cardiovascular morbidity and mortality over and above that demonstrated for simvastatin has been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c5371b4e-33bb-4c31-acff-d438c8f3fc08"></a><a name="section-13.2"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span> (HoFH)</h2>
<p class="First">A double-blind, randomized, 12-week study was performed in patients with a clinical and/or genotypic diagnosis of HoFH. Data were analyzed from a subgroup of patients (n=14) receiving simvastatin 40Â mg at baseline. Increasing the dose of simvastatin from 40 to 80Â mg (n=5) produced a reduction of LDL-C of 13% from baseline on simvastatin 40Â mg. Coadministered ezetimibe and simvastatin equivalent to VYTORIN (10/40 and 10/80 pooled, n=9), produced a reduction of LDL-C of 23% from baseline on simvastatin 40Â mg. In those patients coadministered ezetimibe and simvastatin equivalent to VYTORIN (10/80, n=5), a reduction of LDL-C of 29% from baseline on simvastatin 40Â mg was produced.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_bfcdb206-e37c-4014-8ad5-a82f38b8a06b"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">No. 3874Â â€” Tablets VYTORIN 10/20 are white to off-white capsule-shaped tablets with code â€œ312â€? on one side.</p>
<p>They are supplied as follows: </p>
<p><span class="Bold">NDC</span> 21695-325-30 bottles of 30</p>
<p>No. 3875Â â€” Tablets VYTORIN 10/40 are white to off-white capsule-shaped tablets with code â€œ313â€? on one side.</p>
<p>They are supplied as follows: </p>
<p><span class="Bold">NDC</span> 21695-339-30 bottles of 30</p>
<p>No. 3876Â â€” Tablets VYTORIN 10/80 are white to off-white capsule-shaped tablets with code â€œ315â€? on one side.</p>
<p>They are supplied as follows: </p>
<p><span class="Bold">NDC</span> 21695-827-30 bottles of 30</p>
<p><span class="Italics"><span class="Bold">Storage</span></span></p>
<p>Store at 20-25Â°C (68-77Â°F). [See USP Controlled Room Temperature.] Keep container tightly closed.</p>
<p><span class="Italics"><span class="Bold">Storage of 10,000, 5000, and 2500 count bottles</span></span></p>
<p>Store bottle of 10,000 VYTORIN 10/10 and 10/20, 5000 VYTORIN 10/40, and 2500 VYTORIN 10/80 capsule-shaped tablets at 20-25Â°C (68-77Â°F). [See USP Controlled Room Temperature.] Store in original container until time of use. When product container is subdivided, repackage into a tightly-closed, light-resistant container. Entire contents must be repackaged immediately upon opening.</p>
<p>Manufactured for:<br>MERCK/Schering-Plough Pharmaceuticals<br>North Wales, PA 19454, USA</p>
<p>By:<br>MSD Technology Singapore Pte. Ltd.<br>Singapore 637766</p>
<p>Or</p>
<p>Merck Sharp &amp; Dohme (Italia) S.p.A.<br>Via Emilia, 21<br>27100 â€“ Pavia, Italy</p>
<p>Or</p>
<p>Merck Sharp &amp; Dohme Ltd.<br>Cramlington, Northumberland, UK NE23 3JU</p>
<p>Or</p>
<p>Jointly manufactured by:<br>Merck Sharp &amp; Dohme (Italia) S.p.A.<br>Via Emilia, 21<br>27100 â€“ Pavia, Italy<br>and<br>MSD Technology Singapore Pte. Ltd.<br>Singapore 637766</p>
<p>U.S. Patent Nos. 5,846,966 and RE37,721</p>
<p>Repackaged by:</p>
<p>Rebel Distributors Corp</p>
<p>Thousand Oaks, CA 91320</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_5d2c96ab-cd3f-488c-9fd4-97317a14b928"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">[See <a href="#i4i_section_id_f0d9c410-4d79-4e3e-af29-c83e5263a07f">FDA-Approved Patient Labeling (17.5)</a>.]</span></p>
<p>Patients should be advised to adhere to their National <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Education Program (NCEP)-recommended diet, a regular exercise program, and periodic testing of a fasting lipid panel.</p>
<p><span class="Bold">Patients should be advised about substances they should not take concomitantly with VYTORIN <span class="Italics"> [see <a href="#i4i_section_id_a6c531db-1e1a-436c-aa93-e6c216bde842">Warnings and Precautions (5.1)</a>]</span>. Patients should also be advised to inform other physicians prescribing a new medication that they are taking VYTORIN.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7ad4d9a2-a446-423d-bf78-16a1685d4ca6"></a><a name="section-15.1"></a><p></p>
<h2>17.1 <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle Pain</span></h2>
<p class="First">All patients starting therapy with VYTORIN should be advised of the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and told to report promptly any unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. The risk of this occurring is increased when taking certain types of medication or consuming larger quantities of grapefruit juice. They should discuss all medication, both prescription and over the counter, with their healthcare professional.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0946ea77-d9ca-4b9b-ac32-bd799e8cd169"></a><a name="section-15.2"></a><p></p>
<h2>17.2 Liver Enzymes</h2>
<p class="First">It is recommended that liver function tests be performed before the initiation of VYTORIN, and thereafter when clinically indicated. Patients titrated to the 10/80-mg dose should receive an additional test prior to titration, 3Â months after titration to the 10/80-mg dose, and periodically thereafter (e.g., semiannually) for the first year of treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8a7084aa-91de-41de-9e30-ea39b8b9359b"></a><a name="section-15.3"></a><p></p>
<h2>17.3 Pregnancy</h2>
<p class="First">Women of childbearing age should be advised to use an effective method of birth control to prevent pregnancy while using VYTORIN. Discuss future pregnancy plans with your patients, and discuss when to stop taking VYTORIN if they are trying to conceive. Patients should be advised that if they become pregnant they should stop taking VYTORIN and call their healthcare professional.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a8806a52-2bc4-4e45-b0a7-ba265f22602a"></a><a name="section-15.4"></a><p></p>
<h2>17.4 Breast-feeding</h2>
<p class="First">Women who are breast-feeding should be advised to not use VYTORIN. Patients who have a lipid disorder and are breast-feeding should be advised to discuss the options with their healthcare professional.<br></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f0d9c410-4d79-4e3e-af29-c83e5263a07f"></a><a name="section-15.5"></a><p></p>
<h2>17.5 FDA-Approved Patient Labeling</h2>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_5fa98fc8-942d-4b7b-b3a4-b934caf42e16"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">VYTORIN<span class="Sup">Â®</span> (ezetimibe/simvastatin) Tablets<br>Patient Information about VYTORIN (VI-tor-in)</span><br>Generic name: ezetimibe/simvastatin tablets</p>
<p>Read this information carefully before you start taking VYTORIN. Review this information each time you refill your prescription for VYTORIN as there may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. If you have any questions about VYTORIN, ask your doctor. Only your doctor can determine if VYTORIN is right for you.</p>
<p><span class="Bold">What is VYTORIN?</span></p>
<p>VYTORIN contains two <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-lowering medications, ezetimibe and simvastatin, available as a tablet in four strengths: </p>
<ul>
<li>VYTORIN 10/10 (ezetimibe 10Â mg/simvastatin 10Â mg)</li>
<li>VYTORIN 10/20 (ezetimibe 10Â mg/simvastatin 20Â mg)</li>
<li>VYTORIN 10/40 (ezetimibe 10Â mg/simvastatin 40Â mg)</li>
<li>VYTORIN 10/80 (ezetimibe 10Â mg/simvastatin 80Â mg)</li>
</ul>
<p>VYTORIN is a medicine used to lower levels of total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LDL (bad) <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, and fatty substances called triglycerides in the blood. In addition, VYTORIN raises levels of HDL (good) <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. VYTORIN is for patients who cannot control their <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels by diet and exercise alone. You should stay on a <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-lowering diet while taking this medicine.</p>
<p>VYTORIN works to reduce your <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in two ways. It reduces the <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> absorbed in your digestive tract, as well as the <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> your body makes by itself. VYTORIN does not help you lose weight. VYTORIN has not been shown to reduce <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> more than simvastatin alone.</p>
<p>For more information about <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, see the section called â€œWhat should I know about high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>?â€?</p>
<p><span class="Bold">Who should not take VYTORIN?</span></p>
<p>Do not take VYTORIN:</p>
<ul>
<li>If you are allergic to ezetimibe or simvastatin, the active ingredients in VYTORIN, or to the inactive ingredients. For a list of inactive ingredients, see the â€œInactive ingredientsâ€? section at the end of this information sheet.<br><br>
</li>
<li>If you have active liver disease or repeated blood tests indicating possible liver problems.<br><br>
</li>
<li>If you are pregnant, or think you may be pregnant, or planning to become pregnant or breast-feeding.<br><br>
</li>
<li>If you are a woman of childbearing age, you should use an effective method of birth control to prevent pregnancy while using VYTORIN.</li>
</ul>
<p>VYTORIN has not been studied in children under 10Â years of age. </p>
<p><span class="Bold">What should I tell my doctor before and while taking VYTORIN?</span></p>
<p><span class="Bold">Tell your doctor right away if you experience unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. This is because on rare occasions, muscle problems can be serious, including muscle breakdown resulting in kidney damage.</span></p>
<p>The risk of muscle breakdown is greater at higher doses of VYTORIN.</p>
<p>The risk of muscle breakdown is greater in patients with kidney problems.</p>
<p>Taking VYTORIN with certain substances can increase the risk of muscle problems. It is particularly important to tell your doctor if you are taking any of the following:</p>
<ul>
<li>cyclosporine</li>
<li>danazol</li>
<li>antifungal agents (such as itraconazole or ketoconazole)</li>
<li>fibric acid derivatives (such as gemfibrozil, bezafibrate, or fenofibrate)</li>
<li>the antibiotics erythromycin, clarithromycin, and telithromycin</li>
<li>HIV protease inhibitors (such as indinavir, nelfinavir, ritonavir, and saquinavir)</li>
<li>the antidepressant nefazodone</li>
<li>amiodarone (a drug used to treat an irregular heartbeat)</li>
<li>verapamil or diltiazem (a drug used to treat high blood pressure, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> associated with heart disease, or other heart conditions)</li>
<li>large quantities of grapefruit juice (&gt;1 quart daily)</li>
<li>large doses (â‰¥1Â g/day) of niacin or nicotinic acid</li>
</ul>
<p>Tell your doctor if you are taking niacin or a niacin-containing product, as this may increase your risk of muscle problems, especially if you are Chinese.</p>
<p>It is also important to tell your doctor if you are taking coumarin anticoagulants (drugs that prevent blood clots, such as warfarin).</p>
<p>Tell your doctor about any prescription and nonprescription medicines you are taking or plan to take, including natural or herbal remedies.</p>
<p>Tell your doctor about all your medical conditions including allergies.</p>
<p>Tell your doctor if you:<br><br></p>
<ul>
<li>drink substantial quantities of alcohol or ever had liver problems. VYTORIN may not be right for you. <br><br>
</li>
<li>are pregnant or plan to become pregnant. Do not use VYTORIN if you are pregnant, trying to become pregnant or suspect that you are pregnant. If you become pregnant while taking VYTORIN, stop taking it and contact your doctor immediately.<br><br>
</li>
<li>are breast-feeding. Do not use VYTORIN if you are breast-feeding.</li>
</ul>
<p>Tell other doctors prescribing a new medication that you are taking VYTORIN.</p>
<p><span class="Bold">How should I take VYTORIN?</span></p>
<p>Your doctor has prescribed your dose of VYTORIN. The available doses of VYTORIN are 10/10, 10/20, 10/40, and 10/80. The usual daily starting dose is VYTORINÂ 10/20.<br></p>
<ul>
<li>Take VYTORIN once a day, in the evening, with or without food. <br><br>
</li>
<li>Try to take VYTORIN as prescribed. If you miss a dose, do not take an extra dose. Just resume your usual schedule.<br><br>
</li>
<li>Continue to follow a <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-lowering diet while taking VYTORIN. Ask your doctor if you need diet information.<br><br>
</li>
<li>Keep taking VYTORIN unless your doctor tells you to stop. If you stop taking VYTORIN, your <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> may rise again.</li>
</ul>
<p><span class="Bold">What should I do in case of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>?</span></p>
<p>Contact your doctor immediately.</p>
<p><span class="Bold">What are the possible side effects of VYTORIN?</span></p>
<p>See your doctor regularly to check your <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> level and to check for side effects. Your doctor may do blood tests to check your liver before you start taking VYTORIN and during treatment.</p>
<p>In clinical studies patients reported the following common side effects while taking VYTORIN: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (see What should I tell my doctor before and while taking VYTORIN?).</p>
<p>The following side effects have been reported in general use with VYTORIN or with ezetimibe or simvastatin tablets (tablets that contain the active ingredients of VYTORIN):</p>
<ul><li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue, and/or throat that may cause difficulty in breathing or swallowing (which may require treatment right away), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>; raised red <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, sometimes with target-shaped lesions; <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>; <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>; alterations in some laboratory blood tests; liver problems (sometimes serious); <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the pancreas; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling sensation</span>; <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; <span class="product-label-link" type="condition" conceptid="196456" conceptname="Gallstone">gallstones</span>; <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the gallbladder; trouble sleeping; poor memory; <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>; breathing problems including persistent <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and/or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.</li></ul>
<p>Tell your doctor if you are having these or any other medical problems while on VYTORIN. This is <span class="Underline">not</span> a complete list of side effects. For a complete list, ask your doctor or pharmacist.</p>
<p><span class="Bold">What should I know about high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>?</span></p>
<p><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> is a type of fat found in your blood. <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> comes from two sources. It is produced by your body and it comes from the food you eat. Your total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> is made up of both LDL and HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. </p>
<p>LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> is called â€œbadâ€? <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> because it can build up in the wall of your arteries and form plaque. Over time, plaque build-up can cause a narrowing of the arteries. This narrowing can slow or block blood flow to your heart, brain, and other organs. High LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> is a major cause of heart disease and one of the causes for <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</p>
<p>HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> is called â€œgoodâ€? <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> because it keeps the bad <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> from building up in the arteries. </p>
<p>Triglycerides also are fats found in your body.</p>
<p><span class="Bold">General Information about VYTORIN</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use VYTORIN for a condition for which it was not prescribed. Do not give VYTORIN to other people, even if they have the same condition you have. It may harm them. </p>
<p>This summarizes the most important information about VYTORIN. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about VYTORIN that is written for health professionals. For additional information, visit the following web site: vytorin.com.</p>
<p><span class="Bold">Inactive ingredients:</span></p>
<p>Butylated hydroxyanisole NF, citric acid monohydrate USP, croscarmellose sodium NF, hypromellose USP, lactose monohydrate NF, magnesium stearate NF, microcrystalline cellulose NF, and propyl gallate NF.</p>
<p><br>Issued May 2010</p>
<p>9619517</p>
<p>Manufactured for:<br>Merck/Schering-Plough Pharmaceuticals<br>North Wales, PA 19454, USA</p>
<p>By:<br>MSD Technology Singapore Pte. Ltd.<br>Singapore 637766</p>
<p>Or</p>
<p>Merck Sharp &amp; Dohme (Italia) S.p.A.<br>Via Emilia, 21<br>27100 â€“ Pavia, Italy</p>
<p>Or</p>
<p>Merck Sharp &amp; Dohme Ltd.<br>Cramlington, Northumberland, UK NE23 3JU</p>
<p>Or</p>
<p>Jointly manufactured by:<br>Merck Sharp &amp; Dohme (Italia) S.p.A.<br>Via Emilia, 21<br>27100 â€“ Pavia, Italy<br>and<br>MSD Technology Singapore Pte. Ltd.<br>Singapore 637766</p>
<p>U.S. Patent Nos. 5,846,966 and RE37,721</p>
<p>Repackaged by:</p>
<p>Rebel Distributors Corp</p>
<p>Thousand Oaks, CA 91320</p>
<p><span class="Bold"><br>This is a representative sample of the packaging. Please see How Supplied section for a complete list of available packaging.</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_7e4ba73f-2e52-481e-b233-7f5d1a4e766b"></a><a name="section-17"></a><p></p>
<h1><span class="Bold">PRINCIPAL DISPLAY PANEL - Bottle Label 10/20</span></h1>
<p class="First">VYTORINÂ® 10/20<br>(ezetimibe/simvastatin)</p>
<p>Each tablet contains 10 mg ezetimibe and 20 mg simvastatin.</p>
<p>Store at 20-25Â°C (68-77Â°F). [See USP Controlled Room Temperature.]<br>Keep container tightly closed.</p>
<p>Rx only</p>
<p>USUAL ADULT DOSAGE: See accompanying circular.</p>
<p>30 Tablets</p>
<p>NDC 21695-325-30</p>
<p>Dist. by:<br>MERCK/Schering-Plough Pharmaceuticals<br>North Wales, PA 19454, U. S. A.</p>
<p>Jointly manuf. by:<br>Merck Sharp &amp; Dohme (Italia) S.p.A.<br>Via Emilia, 21<br>27100 - Pavia, Italy<br>and<br>MSD Technology Singapore Pte. Ltd.<br>Singapore 637766</p>
<p>Product of Singapore.</p>
<p>9732402<br>30 | No. 3874</p>
<p>Repackaged by:</p>
<p>Rebel Distributors Corp</p>
<p>Thousand Oaks, CA 91320</p>
<div class="Figure">
<img alt="Vytorin 10/20mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=65e1c3ae-a462-4345-8a28-c7d2c0388af8&amp;name=65e1c3ae-a462-4345-8a28-c7d2c0388af8-03.jpg"><p class="MultiMediaCaption"></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_37d4269e-ca8d-4bba-ab7b-c5a81f6aa1d8"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - Bottle Label 10/40</span></p>
<p>VYTORINÂ® 10/40<br>(ezetimibe/simvastatin)</p>
<p>Each tablet contains 10 mg ezetimibe and 40 mg simvastatin.</p>
<p>Store at 20-25Â°C (68-77Â°F). [See USP Controlled Room Temperature.]<br>Keep container tightly closed.</p>
<p>30 Tablets</p>
<p>NDC 21695-339-30</p>
<p>Rx only</p>
<p>USUAL ADULT DOSAGE: See accompanying circular.</p>
<p>Dist. by:<br>MERCK/Schering-Plough Pharmaceuticals<br>North Wales, PA 19454, U. S. A.</p>
<p>Manuf. by:<br>Merck Sharp &amp; Dohme (Italia) S.p.A.<br>Via Emilia, 21<br>27100 - Pavia, Italy</p>
<p>Formulated in Italy.</p>
<p>9861900<br>30 | No. 3875</p>
<p>Repackaged by:</p>
<p>Rebel Distributors Corp</p>
<p>Thousand Oaks, CA 91320</p>
<div class="Figure">
<img alt="Vytorin 10/40mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=65e1c3ae-a462-4345-8a28-c7d2c0388af8&amp;name=65e1c3ae-a462-4345-8a28-c7d2c0388af8-04.jpg"><p class="MultiMediaCaption"></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_28b6c84e-1d9d-4924-865e-950ad005ba18"></a><a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - Bottle Label 10/80</span></p>
<p>VYTORINÂ® 10/80<br>(ezetimibe/simvastatin)</p>
<p>Each tablet contains 10 mg ezetimibe and 80 mg simvastatin.</p>
<p>Store at 20-25Â°C (68-77Â°F). [See USP Controlled Room Temperature.]<br>Keep container tightly closed.</p>
<p>30 Tablets</p>
<p>NDC 21695-827-30</p>
<p>Rx only</p>
<p>USUAL ADULT DOSAGE: See accompanying circular.</p>
<p>Dist. by:<br>MERCK/Schering-Plough Pharmaceuticals<br>North Wales, PA 19454, U. S. A.</p>
<p>Manuf. by:<br>MSD Technology Singapore Pte. Ltd.<br>Singapore 637766</p>
<p>Product of Singapore.</p>
<p>9732601<br>30 | No. 3876</p>
<p>Repackaged by:</p>
<p>Rebel Distributors Corp</p>
<p>Thousand Oaks, CA 91320</p>
<div class="Figure">
<img alt="Vytorin 10/80mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=65e1c3ae-a462-4345-8a28-c7d2c0388af8&amp;name=65e1c3ae-a462-4345-8a28-c7d2c0388af8-05.jpg"><p class="MultiMediaCaption"></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VYTORINÂ 		
					</strong><br><span class="contentTableReg">ezetimibe and simvastatin tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:21695-325(NDC:66582-312)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ezetimibe</strong> (ezetimibe) </td>
<td class="formItem">ezetimibe</td>
<td class="formItem">10Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>simvastatin</strong> (simvastatin) </td>
<td class="formItem">simvastatin</td>
<td class="formItem">20Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>butylated hydroxyanisole</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>citric acid monohydrate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propyl gallate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">312</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:21695-325-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021687</td>
<td class="formItem">07/23/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VYTORINÂ 		
					</strong><br><span class="contentTableReg">ezetimibe and simvastatin tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:21695-339(NDC:66582-313)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ezetimibe</strong> (ezetimibe) </td>
<td class="formItem">ezetimibe</td>
<td class="formItem">10Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>simvastatin</strong> (simvastatin) </td>
<td class="formItem">simvastatin</td>
<td class="formItem">40Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>butylated hydroxyanisole</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>citric acid monohydrate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propyl gallate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">313</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:21695-339-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021687</td>
<td class="formItem">07/23/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VYTORINÂ 		
					</strong><br><span class="contentTableReg">ezetimibe and simvastatin tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:21695-827(NDC:66582-315)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ezetimibe</strong> (ezetimibe) </td>
<td class="formItem">ezetimibe</td>
<td class="formItem">10Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>simvastatin</strong> (simvastatin) </td>
<td class="formItem">simvastatin</td>
<td class="formItem">80Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>butylated hydroxyanisole</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>citric acid monohydrate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propyl gallate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">315</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:21695-827-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021687</td>
<td class="formItem">07/23/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Rebel Distributors Corp
							(118802834)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Rebel Distributors Corp</td>
<td class="formItem"></td>
<td class="formItem">118802834</td>
<td class="formItem">RELABEL, REPACK</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>65e1c3ae-a462-4345-8a28-c7d2c0388af8</div>
<div>Set id: 65e1c3ae-a462-4345-8a28-c7d2c0388af8</div>
<div>Version: 1</div>
<div>Effective Time: 20101201</div>
</div>
</div>Â <div class="DistributorName">Rebel Distributors Corp</div></p>
</body></html>
